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1. Introduction {#rmb212030-sec-0005}
===============

Adequate growth of the endometrium is indispensable for a successful pregnancy. Women with thin endometria have lower pregnancy rates, largely related to implantation failure.[1](#rmb212030-bib-0001){ref-type="ref"}, [2](#rmb212030-bib-0002){ref-type="ref"}, [3](#rmb212030-bib-0003){ref-type="ref"}, [4](#rmb212030-bib-0004){ref-type="ref"}, [5](#rmb212030-bib-0005){ref-type="ref"}, [6](#rmb212030-bib-0006){ref-type="ref"} The authors recently found high blood impedance in the uterine radial artery in patients with a thin endometrium[4](#rmb212030-bib-0004){ref-type="ref"} and that vitamin E, L‐arginine, and sildenafil citrate treatments, which increase the blood flow of the uterine radial artery, helped to thicken the endometrium.[7](#rmb212030-bib-0007){ref-type="ref"} This suggests that a low level of blood flow to the endometrium reduces its thickness, although it remains unclear why this would result in implantation failure. In order to answer this question, the authors compared the transcriptomes of thin and normal endometrial tissues with a microarray.

2. Materials and Methods {#rmb212030-sec-0006}
========================

2.1. Tissue sampling {#rmb212030-sec-0007}
--------------------

In total, six women with a history of infertility were recruited into the study. All the patients were diagnosed with unexplained infertility after excluding any obvious cause of infertility, such as uterine fibroid, endometriosis, tubal obstruction, and uterine malformation. The patients were classified into two groups, based on the endometrial thickness and level of blood flow impedance in the uterine radial artery. The endometrial thickness was measured at the maximal distance between each myometrial--endometrial interface by using vaginal ultrasonography in the mid‐luteal phase. The level of blood flow impedance in the uterine radial artery was measured as a resistance index with a pulsed Doppler. The cut‐off value of the endometrial thickness and level of blood flow impedance were defined as \<8 mm and ≥0.81 mm, respectively, based on the authors\' previous studies.[4](#rmb212030-bib-0004){ref-type="ref"}, [7](#rmb212030-bib-0007){ref-type="ref"}, [8](#rmb212030-bib-0008){ref-type="ref"} Three patients had a normal‐thickness endometrium (endometrial thickness ≥8 mm) and three patients had a thin endometrium (Thin; endometrial thickness \<8 mm) (Table [1](#rmb212030-tbl-0001){ref-type="table-wrap"}). The endometrial thickness of the normal‐thickness endometrium group and the thin‐endometrium group was 9.53±0.65 and 6.33±0.68 mm, respectively. The difference in the endometrial thickness was significant (*P*=.0042). A high level of blood flow impedance in the uterine radial artery was confirmed only in the patients with a thin endometrium (0.86±0.04 vs 0.76±0.03; *P*=.027). The differences between the groups in age (31.7±3.21 vs 31.3±5.13 years), menstrual cycles (3.00±4.58 and 28.3±1.52 days), and serum levels of estradiol (171.3±16.6 vs 182.1±72.1 pg/mL) and progesterone (15.4±2.3 vs 21.5±7.6 μg/mL) were not significant. The endometrial tissue was obtained during the mid‐luteal phase of the menstrual cycle. Samples of endometrial curettings were washed with saline to remove the blood, immersed in liquid nitrogen, and stored at −80°C until RNA extraction.

###### 

Cases of normal‐thickness and thin endometrium

  Group       Age (years)   Menstrual cycle (days)   Endometrial thickness (mm)   Sampling date (from LMP)   Estradiol (pg/mL)   Progesterone (μg/mL)   Blood flow impedance (RI)
  ----------- ------------- ------------------------ ---------------------------- -------------------------- ------------------- ---------------------- ---------------------------
  Control 1   34            26                       9.5                          20                         166.0               18.0                   0.823
  Control 2   33            29                       1.2                          22                         189.9               14.7                   0.876
  Control 3   28            35                       8.9                          29                         158.0               13.6                   0.893
  Thin 1      37            27                       7.1                          20                         247.5               26.4                   0.759
  Thin 2      30            30                       5.8                          22                         193.9               25.3                   0.750
  Thin 3      27            28                       6.1                          21                         104.8               12.7                   0.781

Control, normal‐thickness endometrium; LMP, last menstrual period; thin, thin endometrium.
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2.2. Transcriptome analysis {#rmb212030-sec-0008}
---------------------------

The total RNAs were isolated from the tissues by using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) and they were reverse‐transcribed by using a QuantiTect Reverse Transcription Kit (Qiagen, Valencia, CA, USA), according to the manufacturer\'s protocol. The transcriptome analysis gene expression was analyzed by using a GeneChip Human Genome U133 Plus 2.0 Array (Affymetrix, Santa Clara, CA, USA) that contained 54 120 probes supporting 18 599 genes, as previously reported.[9](#rmb212030-bib-0009){ref-type="ref"}, [10](#rmb212030-bib-0010){ref-type="ref"} Briefly, the target cDNA was prepared from 200 ng of total RNA with the Ambion WT Expression kit (Ambion, Austin, TX, USA) and the Affymetrix GeneChip WT Terminal Labeling kit (Affymetrix). Hybridization to the microarrays, washing, staining, and scanning were performed by using the GeneChip system (Affymetrix), which was composed of the Scanner 3000 7G Workstation Fluidics 450 (Affymetrix) and the Hybridization Oven 645 (Affymetrix). The scanned image data were processed by using a gene expression analysis with the Partek Genomics Suite 6.5 software program (Partech, Munster, Germany). Then, 2000 randomly selected genes were used for the hierarchical clustering analysis and principal component analysis (PCA). Those genes whose expressions in the thin and normal endometrium differed by at least a factor of 2 and that had a false discovery rate of \<.05 were judged as showing a significant difference.

2.3. Bioinformatics {#rmb212030-sec-0009}
-------------------

A hierarchical clustering and a PCA were conducted in R v. 3.2.4.[11](#rmb212030-bib-0011){ref-type="ref"} DAVID Bioinformatics Resources v. 6.7 (<http://david.abcc.ncifcrf.gov/home.jsp>) was used to determine whether the functional annotation of the differentially expressed genes was enriched for specific Gene Ontology (GO) terms and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways.[12](#rmb212030-bib-0012){ref-type="ref"} Statistical significance was assessed with a modified Fisher\'s exact test. In the GO and KEGG analyses, *P*\<.01 and *P*\<.05, respectively, were considered to indicate significant enrichment. All the information from the GO and KEGG pathway analyses is shown in Tables [S1](#rmb212030-sup-0001){ref-type="supplementary-material"}‐[S4](#rmb212030-sup-0004){ref-type="supplementary-material"}.

3. Results {#rmb212030-sec-0010}
==========

3.1. Comparison of the whole mRNA expression profiles of the normal and thin endometrial tissues {#rmb212030-sec-0011}
------------------------------------------------------------------------------------------------

Figure [1](#rmb212030-fig-0001){ref-type="fig"} shows the mRNA expression profiles in the thin and normal endometrial tissues (n=3 for each). The hierarchical dendrogram clearly separated the thin and the control endometria. The PCA (Figure [2](#rmb212030-fig-0002){ref-type="fig"}) also clearly separated the thin and the control endometria.

![Heat map and hierarchical clustering of the mRNA expression profiles of patients with thin and normal (control) endometria. The mRNA expression profiles of the thin endometrium (Thin 1, Thin 2, and Thin 3) and the normal‐thickness endometrium (Control 1, Control 2, and Control 3) were compared. The *x*‐axis represents the samples and the *y*‐axis represents the gene clusters. The heat map in hierarchical clustering analysis indicates the mRNA expression levels from low (red) to high (yellow)](RMB2-16-206-g001){#rmb212030-fig-0001}

![Principal component analysis of the mRNA expression profiles of patients with thin and normal (control) endometria. The mRNA expression profiles of the thin endometrium (Thin 1, Thin 2, and Thin 3) and the normal‐thickness endometrium (Control 1, Control 2, and Control 3) were compared. The *y*‐axis and the *x*‐axis show the principal component numbers, respectively](RMB2-16-206-g002){#rmb212030-fig-0002}

3.2. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway analyses of the up‐regulated genes in the thin endometrium {#rmb212030-sec-0012}
---------------------------------------------------------------------------------------------------------------------------------

In the thin‐endometrium group, 318 genes were up‐regulated and 322 genes were down‐regulated, compared to the control endometrium group (Tables [S5](#rmb212030-sup-0005){ref-type="supplementary-material"} and [S6](#rmb212030-sup-0006){ref-type="supplementary-material"}). The up‐regulated genes in the thin endometrium were related to immunity processes, such as the "response to external stimulus," "defense response," "leukocyte mediated immunity," "immune response," "immune effector process," and "regulation of immune system process" (Tables [2](#rmb212030-tbl-0002){ref-type="table-wrap"} and [S1](#rmb212030-sup-0001){ref-type="supplementary-material"}). These GO terms included genes for interferon gamma (*IFN‐*γ), cytotoxic T‐lymphocyte proteinase 1 (*GZMA*) and 2 (*GZMB*), tumor necrosis factor ligand superfamily member 6 (*FASLG*), and tumor necrosis factor alpha (*TNF‐*α)‐induced genes, such as TNF‐α‐induced protein 2 (*TNFAIP2)* and 6 (*TNFAIP6*).

###### 

Gene ontology analysis for the genes that were up‐regulated in the thin endometrium

  Category        Term                                                                   Count   *P* value    Gene
  --------------- ---------------------------------------------------------------------- ------- ------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  GOTERM_BP_FAT   Response to external stimulus                                          70      1.16E‐09     *ARSB*,*FGF18*,*NRP1*,*MMP7*,***FASLG***,*PMAIP1*,*FOS*,*CD96*,*MYOCD*,*APOD*,*HPSE*,*RNASE7*,***IFNG***,*SLC2A1*,*CALCRL*,*CFI*,*LBP*,*MX1*,*ANGPT2*,*FCGR3B*,*F11*,*ZFP36*,*TRPM8*,*KIF5A*,*SOCS3*,*GNLY*,*PIM1*,*FOSB*,*PLAUR*,***TNFAIP6***,*SSTR2*,*THBD*,*ADM*,*IL20RB*,*TREM1*,*DPF3*,*PRF1*,*RBP1*,*ASS1*,*CCR1*,*STATH*,*CXCL2*,*GAST*,*TRDC*,*CCL4*,*IRAK3*,*RAC2*,*INPP5F*,*ARNTL2*,*BHLHE40*,*PTPRC*,*ST6GAL1*,*SLC8A1*,*VAV3*,*AIMP1*,*CFB*,*LMCD1*,*NR4A1*,*NR4A3*,*COTL1*,*PLAC8*,*SOD2*,*CORO1A*,*CD55*,*SLC7A2*,*CXCL13*,*CMTM7*,*CP*,*XCL1*,*HTR2A*
  GOTERM_BP_FAT   Defense response                                                       56      3.70E‐09     *KLRC2*,*IL19*,*PMAIP1*,*FOS*,*CD96*,*APOD*,*RNASE7*,***IFNG***,*VNN1*,*CALCRL*,*CFI*,*LBP*,*MX1*,*KLRD1*,*FCGR3B*,*DPP4*,*ZFP36*,*EGR1*,*NFKBIZ*,*SOCS3*,*GNLY*,***GZMB***,*CD84*,***TNFAIP6***,*OR2H2*,*CAMK4*,*ADM*,*IL20RB*,*TREM1*,*KIR3DL1*,*KIR2DL4*,*KIR3DL2*,*DPF3*,*PRF1*,*ASS1*,*CCR1*,*CXCL2*,*STATH*,*TRDC*,*C1S*,*CCL4*,*IRAK3*,*RASGRP1*,*BLNK*,*PTPRC*,*AIMP1*,*CFB*,*LMCD1*,*COTL1*,*PLAC8*,*CD55*,*CORO1A*,*SLC7A2*,*CXCL13*,*C1RL*,*XCL1*
  GOTERM_BP_FAT   Leukocyte mediated immunity                                            21      1.62E‐07     *PTPRC*,*KLRC2*,***GZMB***,*TRDC*,*C1S*,*NR4A3*,*CD84*,*CD96*,*CORO1A*,*CD55*,*RAC2*,*CAMK4*,*IL20RB*,*RASGRP1*,***IFNG***,*C1RL*,*TREM1*,*CFI*,*XCL1*,*KLRD1*,*KIR3DL1*
  GOTERM_BP_FAT   Immune response                                                        50      1.99E‐07     *PRF1*,*KLRC2*,*ASS1*,*CCR1*,*IL19*,*CXCL2*,***FASLG***,*C1S*,*TRDC*,*ZEB1*,*CCL4*,*CD96*,*IRAK3*,*FOS*,*RAC2*,*RNASE7*,*RASGRP1*,***IFNG***,*VNN1*,*CFI*,*LBP*,*MX1*,*FCGR3B*,*KLRD1*,*BLNK*,*EGR1*,*PTPRC*,*ST6GAL1*,*VAV3*,*CFB*,*SOCS3*,***GZMA***,***GZMB***,*NR4A3*,*PRKCB*,*CTSW*,*CD84*,*CD38*,*CORO1A*,*CD55*,*MYO10*,*RGS1*,*IL20RB*,*ADM*,*CAMK4*,*CXCL13*,*C1RL*,*TREM1*,*XCL1*,*KIR3DL1*
  GOTERM_BP_FAT   Immune effector process                                                34      2.07E‐07     *DPF3*,*PRF1*,*RBP4*,*KLRC2*,*PMAIP1*,*TRDC*,*C1S*,*CD96*,*IRAK3*,*RAC2*,*RASGRP1*,***IFNG***,*LBP*,*CFI*,*MX1*,*FCGR3B*,*KLRD1*,*PTPRC*,*VAV3*,*AIMP1*,*CFB*,*LMCD1*,***GZMB***,*NR4A3*,*CD84*,*MYO10*,*CD55*,*CORO1A*,*IL20RB*,*CAMK4*,*C1RL*,*TREM1*,*XCL1*,*KIR3DL1*
  GOTERM_BP_FAT   Regulation of immune system process                                    46      1.96E‐06     *DPF3*,*RBP4*,*RBP1*,*CCR1*,*CXCL2*,*C1S*,*TRDC*,*ZEB1*,*CCL4*,*FOS*,*IRAK3*,*CD96*,*CDKN2A*,*RAC2*,*APOD*,*RASGRP1*,***IFNG***,*VNN1*,*LBP*,*CFI*,*FCGR3B*,*KLRD1*,*DPP4*,*ZFP36*,*PTPRC*,*VAV3*,*SOCS3*,*CFB*,*LMCD1*,*NR4A3*,*PRKCB*,*CD84*,*CD38*,*CD55*,*MYO10*,*CORO1A*,*CAMK4*,*IL20RB*,*SLC7A2*,*CXCL13*,*C1RL*,*TREM1*,*XCL1*,*KIR3DL1*,*KIR2DL4*,*KIR3DL2*
  GOTERM_CC_FAT   Extracellular space                                                    47      2.70E‐06     *RBP4*,*FGF18*,*NRP1*,*CXCL2*,*IL19*,*MMP7*,***FASLG***,*GAST*,*C1S*,*TRDC*,*SFN*,*CCL4*,*MTHFD2*,*APOD*,***IFNG***,*SLC2A1*,*LBP*,*CFI*,*ANGPT2*,*QSOX1*,*SRGN*,*F11*,*AIMP1*,*CFB*,*GNLY*,*HSPG2*,*LMCD1*,*IGFALS*,*COL25A1*,*CTSW*,*PROM1*,*MMP10*,***TNFAIP6***,*DKK1*,*THBD*,*ADM*,*SERPINB5*,*CXCL13*,*FABP3*,*C1RL*,*CMTM7*,*VCAN*,*IGFBP1*,*CP*,*XCL1*,***TNFAIP2***,*HABP2*
  GOTERM_BP_FAT   Vasculature development                                                26      5.11E‐06     *FGFR2*,*ZFAND5*,*FGF18*,*NRP1*,*LEPR*,***FASLG***,*APOD*,*MYOCD*,*HPSE*,***IFNG***,*ROBO4*,*CALCRL*,*ANGPT2*,*THBS2*,*EGR1*,*VAV3*,*AIMP1*,*SOCS3*,*HSPG2*,*NR4A1*,*PRKCB*,*ADM*,*CXCL13*,*SIX1*,*HIF3A*,***TNFAIP2***
  GOTERM_BP_FAT   Leukocyte activation                                                   29      7.06E‐06     *PRF1*,*LEPR*,*ZEB1*,*TRDC*,*CDKN2A*,*RAC2*,*RASGRP1*,***IFNG***,*VNN1*,*LBP*,*DPP4*,*BLNK*,*EGR1*,*PTPRC*,*IL2RB*,*VAV3*,*IKZF1*,*DOCK8*,*NR4A3*,*PRKCB*,*CD84*,*CD38*,*CORO1A*,*CD55*,*IL20RB*,*CAMK4*,*SLC7A2*,*CMTM7*,*XCL1*
  GOTERM_BP_FAT   Lymphocyte mediated immunity                                           16      1.17E‐05     *PTPRC*,*KLRC2*,***GZMB***,*TRDC*,*C1S*,*CD96*,*CORO1A*,*CD55*,*IL20RB*,*RASGRP1*,***IFNG***,*C1RL*,*CFI*,*XCL1*,*KLRD1*,*KIR3DL1*
  GOTERM_BP_FAT   Inflammatory response                                                  26      1.19E‐05     *ZFP36*,*NFKBIZ*,*AIMP1*,*ASS1*,*SOCS3*,*CFB*,*CCR1*,*IL19*,*CXCL2*,*CCL4*,*FOS*,*CD96*,***TNFAIP6***,*CD55*,*CAMK4*,*IL20RB*,*APOD*,*SLC7A2*,*CXCL13*,*RASGRP1*,*VNN1*,*LBP*,*CFI*,*CALCRL*,*XCL1*,*BLNK*
  GOTERM_BP_FAT   Leukocyte migration                                                    19      1.42E‐05     *VAV3*,*AIMP1*,*CCR1*,*CXCL2*,*DOCK8*,*CCL4*,*MMP1*,*SLC7A11*,*CD84*,*CORO1A*,*THBD*,*RAC2*,*APOD*,*CXCL13*,***IFNG***,*TREM1*,*LBP*,*XCL1*,*ANGPT2*
  GOTERM_BP_FAT   Locomotion                                                             45      1.59E‐05     *ARSB*,*ZFAND5*,*FGF18*,*NRP1*,*CCR1*,*CXCL2*,*FERMT1*,*CCL4*,*MMP1*,*DNAH6*,*NPHP4*,*RAC2*,*APOD*,***IFNG***,*ROBO4*,*INPP5F*,*LBP*,*DEPDC1B*,*ANGPT2*,*DPP4*,*PTPRC*,*SLC8A1*,*ST6GAL1*,*SATB2*,*S100P*,*VAV3*,*AIMP1*,*KIF5A*,*NR4A1*,*DOCK7*,*DOCK8*,*NR4A3*,*SLC7A11*,*PLAUR*,*CD84*,*MMP10*,***TNFAIP6***,*CORO1A*,*THBD*,*CXCL13*,*SIX1*,*CMTM7*,*VCAN*,*TREM1*,*XCL1*
  GOTERM_BP_FAT   Cell activation                                                        32      1.61E‐05     *PRF1*,*LEPR*,*ZEB1*,*TRDC*,*CDKN2A*,*RAC2*,*MYOCD*,*RASGRP1*,***IFNG***,*VNN1*,*LBP*,*DPP4*,*BLNK*,*EGR1*,*PTPRC*,*IL2RB*,*VAV3*,*IKZF1*,*DOCK8*,*NR4A3*,*SLC7A11*,*PRKCB*,*CD84*,*CD38*,*CORO1A*,*CD55*,*THBD*,*IL20RB*,*CAMK4*,*SLC7A2*,*CMTM7*,*XCL1*
  GOTERM_BP_FAT   Regulation of response to external stimulus                            30      1.68E‐05     *FGF18*,*DPF3*,*NRP1*,*CCR1*,*CXCL2*,*CCL4*,*RAC2*,*APOD*,*HPSE*,*INPP5F*,*CALCRL*,*CFI*,*LBP*,*FCGR3B*,*ANGPT2*,*ZFP36*,*F11*,*ST6GAL1*,*CFB*,*SOCS3*,*LMCD1*,*PLAUR*,***TNFAIP6***,*CD55*,*THBD*,*IL20RB*,*CXCL13*,*SLC7A2*,*TREM1*,*XCL1*
  GOTERM_BP_FAT   Blood vessel development                                               24      1.89E‐05     *EGR1*,*FGFR2*,*FGF18*,*NRP1*,*VAV3*,*AIMP1*,*SOCS3*,*LEPR*,*HSPG2*,***FASLG***,*NR4A1*,*PRKCB*,*MYOCD*,*APOD*,*ADM*,*HPSE*,*SIX1*,***IFNG***,*ROBO4*,*HIF3A*,*CALCRL*,*THBS2*,***TNFAIP2***,*ANGPT2*
  GOTERM_BP_FAT   Cardiovascular system development                                      32      3.29E‐05     *FGFR2*,*ZFAND5*,*FGF18*,*RBP4*,*NRP1*,*LEPR*,*PDLIM3*,***FASLG***,*ZIC3*,*APOD*,*MYOCD*,*HPSE*,***IFNG***,*ROBO4*,*CALCRL*,*ANGPT2*,*THBS2*,*EGR1*,*SLC8A1*,*VAV3*,*AIMP1*,*SOCS3*,*HSPG2*,*NR4A1*,*PRKCB*,*SOD2*,*DKK1*,*ADM*,*CXCL13*,*SIX1*,*HIF3A*,***TNFAIP2***
  GOTERM_BP_FAT   Circulatory system development                                         32      3.29E‐05     *FGFR2*,*ZFAND5*,*FGF18*,*RBP4*,*NRP1*,*LEPR*,*PDLIM3*,***FASLG***,*ZIC3*,*APOD*,*MYOCD*,*HPSE*,***IFNG***,*ROBO4*,*CALCRL*,*ANGPT2*,*THBS2*,*EGR1*,*SLC8A1*,*VAV3*,*AIMP1*,*SOCS3*,*HSPG2*,*NR4A1*,*PRKCB*,*SOD2*,*DKK1*,*ADM*,*CXCL13*,*SIX1*,*HIF3A*,***TNFAIP2***
  GOTERM_BP_FAT   Lymphocyte activation                                                  25      3.54E‐05     *PRF1*,*LEPR*,*TRDC*,*ZEB1*,*CDKN2A*,*RAC2*,*RASGRP1*,***IFNG***,*VNN1*,*DPP4*,*BLNK*,*EGR1*,*PTPRC*,*IL2RB*,*VAV3*,*IKZF1*,*DOCK8*,*PRKCB*,*CD38*,*CD55*,*CORO1A*,*IL20RB*,*CAMK4*,*CMTM7*,*XCL1*
  GOTERM_BP_FAT   Blood vessel morphogenesis                                             21      4.88E‐05     *FGFR2*,*FGF18*,*NRP1*,*VAV3*,*AIMP1*,*LEPR*,*HSPG2*,*NR4A1*,***FASLG***,*PRKCB*,*MYOCD*,*APOD*,*ADM*,*HPSE*,*SIX1*,*ROBO4*,*HIF3A*,*CALCRL*,*THBS2*,***TNFAIP2***,*ANGPT2*
  GOTERM_BP_FAT   Angiogenesis                                                           19      4.88E‐05     *FGFR2*,*FGF18*,*NRP1*,*VAV3*,*AIMP1*,*LEPR*,*HSPG2*,*NR4A1*,***FASLG***,*PRKCB*,*APOD*,*ADM*,*HPSE*,*ROBO4*,*HIF3A*,*CALCRL*,*THBS2*,***TNFAIP2***,*ANGPT2*
  GOTERM_BP_FAT   Negative regulation of multicellular organismal process                33      6.30E‐05     *RBP4*,*NRP1*,*CCR1*,*STATH*,***FASLG***,*CD96*,*IRAK3*,*CDKN2A*,*APOD*,*MYOCD*,***IFNG***,*INPP5F*,*LBP*,*CALCRL*,*ANGPT2*,*THBS2*,*SRGN*,*NR2F1*,*ZFP36*,*F11*,*ANXA4*,*PLAUR*,*PLAC8*,*CD84*,*CD38*,*DKK1*,*THBD*,*ADM*,*IL20RB*,*CXCL13*,*SIX1*,*ID4*,*XCL1*
  GOTERM_BP_FAT   Regulation of cell activation                                          21      7.32E‐05     *PTPRC*,*VAV3*,*ZEB1*,*TRDC*,*NR4A3*,*CD84*,*CD38*,*CORO1A*,*CD55*,*THBD*,*CDKN2A*,*RAC2*,*CAMK4*,*IL20RB*,*SLC7A2*,*RASGRP1*,***IFNG***,*VNN1*,*LBP*,*XCL1*,*DPP4*
  GOTERM_BP_FAT   Cell motility                                                          39      7.52E‐05     *ARSB*,*ZFAND5*,*FGF18*,*NRP1*,*CCR1*,*CXCL2*,*FERMT1*,*CCL4*,*MMP1*,*DNAH6*,*NPHP4*,*RAC2*,*APOD*,***IFNG***,*ROBO4*,*LBP*,*DEPDC1B*,*ANGPT2*,*DPP4*,*PTPRC*,*SLC8A1*,*SATB2*,*S100P*,*VAV3*,*AIMP1*,*NR4A1*,*DOCK7*,*DOCK8*,*SLC7A11*,*CD84*,*MMP10*,***TNFAIP6***,*CORO1A*,*THBD*,*CXCL13*,*SIX1*,*VCAN*,*TREM1*,*XCL1*
  GOTERM_BP_FAT   Localization of cell                                                   39      7.52E‐05     *ARSB*,*ZFAND5*,*FGF18*,*NRP1*,*CCR1*,*CXCL2*,*FERMT1*,*CCL4*,*MMP1*,*DNAH6*,*NPHP4*,*RAC2*,*APOD*,***IFNG***,*ROBO4*,*LBP*,*DEPDC1B*,*ANGPT2*,*DPP4*,*PTPRC*,*SLC8A1*,*SATB2*,*S100P*,*VAV3*,*AIMP1*,*NR4A1*,*DOCK7*,*DOCK8*,*SLC7A11*,*CD84*,*MMP10*,***TNFAIP6***,*CORO1A*,*THBD*,*CXCL13*,*SIX1*,*VCAN*,*TREM1*,*XCL1*
  GOTERM_BP_FAT   Regulation of leukocyte activation                                     20      8.61E‐05     *PTPRC*,*VAV3*,*ZEB1*,*TRDC*,*NR4A3*,*CD84*,*CD38*,*CORO1A*,*CD55*,*CDKN2A*,*RAC2*,*CAMK4*,*IL20RB*,*SLC7A2*,*RASGRP1*,***IFNG***,*VNN1*,*LBP*,*XCL1*,*DPP4*
  GOTERM_BP_FAT   Regulation of immune effector process                                  19      8.63E‐05     *PTPRC*,*RBP4*,*DPF3*,*CFB*,*LMCD1*,*NR4A3*,*CD84*,*CD96*,*IRAK3*,*CD55*,*RAC2*,*IL20RB*,*RASGRP1*,***IFNG***,*TREM1*,*CFI*,*LBP*,*XCL1*,*FCGR3B*
  GOTERM_CC_FAT   Extracellular region part                                              88      9.24E‐05     *ARSB*,*FGF18*,*NRP1*,*THRB*,*FAM20A*,*IL19*,*MMP7*,***FASLG***,*AURKB*,*MMP1*,*MTHFD2*,*APOD*,*HPSE*,*RNASE7*,*DMKN*,*SLC2A1*,***IFNG***,*ROBO4*,*VNN1*,*CFI*,*LBP*,*DPP6*,*ANGPT2*,*FCGR3B*,*DPP4*,*F11*,*GSTT2B*,*GNLY*,*IGFALS*,*COL25A1*,*PADI1*,*CTSW*,*PLAUR*,*PRKCB*,*CD84*,*MMP10*,***TNFAIP6***,*CD38*,*THBD*,*CAMK4*,*ADM*,*SERPINB5*,*CYBRD1*,*VCAN*,*SLC38A1*,*COL24A1*,***TNFAIP2***,*PPFIA2*,*RBP4*,*ASS1*,*CXCL2*,*GAST*,*C1S*,*SFN*,*TRDC*,*CCL4*,*LAMB3*,*RAC2*,*THBS2*,*QSOX1*,*SRGN*,*PTPRC*,*GPR155*,*ST6GAL1*,*VAV3*,*S100P*,*AIMP1*,*CFB*,*LMCD1*,*HSPG2*,*COTL1*,*ANXA4*,*SOD2*,*PROM1*,*CORO1A*,*CD55*,*DKK1*,*C1ORF116*,*CXCL13*,*FABP3*,*C1RL*,*CMTM7*,*H3F3B*,*IGFBP1*,*CP*,*XCL1*,*FABP5*,*HABP2*
  GOTERM_BP_FAT   Response to biotic stimulus                                            32      9.65E‐05     *PRF1*,*DPF3*,*ASS1*,*CXCL2*,*STATH*,***FASLG***,*PMAIP1*,*TRDC*,*CCL4*,*FOS*,*CD96*,*IRAK3*,*RNASE7*,***IFNG***,*LBP*,*MX1*,*FCGR3B*,*ZFP36*,*PTPRC*,*AIMP1*,*SOCS3*,*GNLY*,*LMCD1*,*COTL1*,*PLAC8*,*SOD2*,*CD55*,*THBD*,*ADM*,*CXCL13*,*TREM1*,*XCL1*
  GOTERM_BP_FAT   Anatomical structure formation involved in morphogenesis               35      9.69E‐05     *FGFR2*,*RBP4*,*FGF18*,*NRP1*,*FAM20A*,*ABLIM3*,*LEPR*,*BBS9*,***FASLG***,*MTHFD1L*,*WDR74*,*LAMB3*,*APOD*,*HPSE*,*ROBO4*,*CALCRL*,*LMOD3*,*ANGPT2*,*THBS2*,*VAV3*,*AIMP1*,*HSPG2*,*NR4A1*,*NR4A3*,*PRKCB*,*PROM1*,*DUSP5*,*DKK1*,*ADM*,*CXCL13*,*ETS2*,*SIX1*,*HIF3A*,***TNFAIP2***,*DUSP6*
  GOTERM_BP_FAT   Cell chemotaxis                                                        14      1.00E‐04     *FGF18*,*NRP1*,*VAV3*,*CCR1*,*CXCL2*,*NR4A1*,*CCL4*,*CORO1A*,*RAC2*,*CXCL13*,***IFNG***,*LBP*,*TREM1*,*XCL1*
  GOTERM_BP_FAT   Response to other organism                                             31      1.05E‐04     *PRF1*,*DPF3*,*ASS1*,*CXCL2*,*STATH*,***FASLG***,*PMAIP1*,*TRDC*,*CCL4*,*FOS*,*CD96*,*IRAK3*,*RNASE7*,***IFNG***,*LBP*,*MX1*,*FCGR3B*,*ZFP36*,*PTPRC*,*AIMP1*,*SOCS3*,*GNLY*,*LMCD1*,*COTL1*,*PLAC8*,*SOD2*,*THBD*,*ADM*,*CXCL13*,*TREM1*,*XCL1*
  GOTERM_BP_FAT   Response to external biotic stimulus                                   31      1.05E‐04     *PRF1*,*DPF3*,*ASS1*,*CXCL2*,*STATH*,***FASLG***,*PMAIP1*,*TRDC*,*CCL4*,*FOS*,*CD96*,*IRAK3*,*RNASE7*,***IFNG***,*LBP*,*MX1*,*FCGR3B*,*ZFP36*,*PTPRC*,*AIMP1*,*SOCS3*,*GNLY*,*LMCD1*,*COTL1*,*PLAC8*,*SOD2*,*THBD*,*ADM*,*CXCL13*,*TREM1*,*XCL1*
  GOTERM_BP_FAT   Cell proliferation                                                     49      1.29E‐04     *FGFR2*,*RBP4*,*FGF18*,*NRP1*,*FERMT1*,***FASLG***,*PMAIP1*,*ZEB1*,*AURKB*,*SFN*,*FAM83B*,*CDKN2A*,*APOD*,*RAC2*,*MYOCD*,*HPSE*,***IFNG***,*MTCP1*,*CALCRL*,*QSOX1*,*DPP4*,*EGR1*,*ZFP36*,*PTPRC*,*ST6GAL1*,*VAV3*,*TRNP1*,*AIMP1*,*PIM1*,*NR4A1*,*DOCK7*,*NR4A3*,*DOCK8*,*PLAC8*,*SOD2*,*CD38*,*SSTR2*,*CORO1A*,*CD55*,*IL20RB*,*ADM*,*SERPINB5*,*SIX1*,*FABP3*,*H3F3B*,*ID4*,*XCL1*,*EMP1*,*HTR2A*
  GOTERM_CC_FAT   Extracellular region                                                   100     1.29E‐04     *ARSB*,*FGF18*,*NRP1*,*THRB*,*FAM20A*,*LEPR*,*IL19*,*MMP7*,***FASLG***,*AURKB*,*MMP1*,*MTHFD2*,*APOD*,*HPSE*,*DMKN*,*RNASE7*,*SLC2A1*,***IFNG***,*ROBO4*,*VNN1*,*LBP*,*CFI*,*DPP6*,*GFOD1*,*FCGR3B*,*ANGPT2*,*CSF2RA*,*DPP4*,*F11*,*GSTT2B*,***GZMA***,*GNLY*,*IGFALS*,*COL25A1*,*PADI1*,*PRKCB*,*PLAUR*,*CTSW*,*CD84*,*MMP10*,*CD38*,***TNFAIP6***,*PSG9*,*THBD*,*ADM*,*CAMK4*,*SERPINB5*,*CYBRD1*,*VCAN*,*SLC38A1*,*TREM1*,*COL24A1*,***TNFAIP2***,*FGFR2*,*PPFIA2*,*PRF1*,*RBP4*,*ASS1*,*STATH*,*CXCL2*,*GAST*,*C1S*,*SFN*,*TRDC*,*CCL4*,*FAM19A5*,*LAMB3*,*RAC2*,*GLIPR1*,*QSOX1*,*THBS2*,*SRGN*,*PTPRC*,*GPR155*,*ST6GAL1*,*S100P*,*VAV3*,*AIMP1*,*CFB*,*HSPG2*,*LMCD1*,*GRIA3*,*COTL1*,*ANXA4*,*SOD2*,*PROM1*,*CD55*,*CORO1A*,*C1ORF116*,*DKK1*,*CXCL13*,*FABP3*,*C1RL*,*CMTM7*,*H3F3B*,*CP*,*IGFBP1*,*XCL1*,*FABP5*,*HABP2*
  GOTERM_BP_FAT   Regulation of cell proliferation                                       43      1.36E‐04     *FGFR2*,*RBP4*,*FGF18*,*NRP1*,*CXCL2*,***FASLG***,*SFN*,*PMAIP1*,*ZEB1*,*CDKN2A*,*RAC2*,*MYOCD*,*APOD*,*HPSE*,***IFNG***,*CHST11*,*CALCRL*,*QSOX1*,*DPP4*,*ZFP36*,*EGR1*,*PTPRC*,*ST6GAL1*,*VAV3*,*AIMP1*,*TRNP1*,*NR4A1*,*NR4A3*,*PLAC8*,*SOD2*,*CD38*,*SSTR2*,*CD55*,*CORO1A*,*IL20RB*,*ADM*,*SERPINB5*,*CXCL13*,*SIX1*,*FABP3*,*ID4*,*XCL1*,*HTR2A*
  GOTERM_BP_FAT   Movement of cell or subcellular component                              47      1.38E‐04     *ARSB*,*ZFAND5*,*DNAH10*,*FGF18*,*NRP1*,*CCR1*,*CXCL2*,*FERMT1*,*CCL4*,*MMP1*,*DNAH6*,*NPHP4*,*RAC2*,*APOD*,*RASGRP1*,***IFNG***,*ROBO4*,*INPP5F*,*VNN1*,*LBP*,*DEPDC1B*,*ANGPT2*,*DPP4*,*PTPRC*,*SLC8A1*,*SATB2*,*S100P*,*VAV3*,*AIMP1*,*KIF5A*,*NR4A1*,*DOCK7*,*DOCK8*,*NR4A3*,*SLC7A11*,*PLAUR*,*CD84*,*MMP10*,***TNFAIP6***,*CORO1A*,*THBD*,*SERPINB5*,*CXCL13*,*SIX1*,*VCAN*,*TREM1*,*XCL1*
  GOTERM_MF_FAT   Serine‐type peptidase activity                                         14      1.52E‐04     *F11*,***GZMA***,*CFB*,*MMP7*,***GZMB***,*C1S*,*TMPRSS3*,*MMP1*,*MMP10*,*C1RL*,*CFI*,*DPP6*,*DPP4*,*HABP2*
  GOTERM_BP_FAT   Regulation of immune response                                          29      1.58E‐04     *TRDC*,*C1S*,*FOS*,*CD96*,*IRAK3*,*RAC2*,*RASGRP1*,***IFNG***,*LBP*,*CFI*,*KLRD1*,*PTPRC*,*VAV3*,*SOCS3*,*CFB*,*NR4A3*,*PRKCB*,*CD84*,*CD38*,*CD55*,*MYO10*,*IL20RB*,*CXCL13*,*C1RL*,*TREM1*,*XCL1*,*KIR3DL1*,*KIR3DL2*,*KIR2DL4*
  GOTERM_BP_FAT   Cell migration                                                         35      1.68E‐04     *ARSB*,*ZFAND5*,*FGF18*,*NRP1*,*CCR1*,*CXCL2*,*FERMT1*,*CCL4*,*MMP1*,*RAC2*,*APOD*,***IFNG***,*LBP*,*DEPDC1B*,*ANGPT2*,*DPP4*,*PTPRC*,*SLC8A1*,*SATB2*,*S100P*,*VAV3*,*AIMP1*,*NR4A1*,*DOCK7*,*DOCK8*,*SLC7A11*,*CD84*,***TNFAIP6***,*CORO1A*,*THBD*,*CXCL13*,*SIX1*,*VCAN*,*TREM1*,*XCL1*
  GOTERM_MF_FAT   Serine hydrolase activity                                              14      1.70E‐04     *F11*,***GZMA***,*CFB*,*MMP7*,***GZMB***,*C1S*,*TMPRSS3*,*MMP1*,*MMP10*,*C1RL*,*CFI*,*DPP6*,*DPP4*,*HABP2*
  GOTERM_BP_FAT   Cell adhesion                                                          45      1.76E‐04     *PPFIA2*,*ASS1*,*SNX5*,*CCR1*,*LEPR*,*FERMT1*,*CLDN10*,*SFN*,*ZEB1*,*CCL4*,*CD96*,*LAMB3*,*NPHP4*,*CDKN2A*,*RAC2*,*APOD*,*HPSE*,*RASGRP1*,***IFNG***,*VNN1*,*THBS2*,*ANGPT2*,*DPP4*,*EGR1*,*PTPRC*,*ST6GAL1*,*S100P*,*VAV3*,*AIMP1*,*MAGI1*,*IGFALS*,*DOCK8*,*NR4A3*,*SLC7A11*,*CD84*,***TNFAIP6***,*MYO10*,*CD55*,*CORO1A*,*CAMK4*,*IL20RB*,*CXCL13*,*VCAN*,*XCL1*,*HABP2*
  GOTERM_BP_FAT   Biological adhesion                                                    45      1.91E‐04     *PPFIA2*,*ASS1*,*SNX5*,*CCR1*,*LEPR*,*FERMT1*,*CLDN10*,*SFN*,*ZEB1*,*CCL4*,*CD96*,*LAMB3*,*NPHP4*,*CDKN2A*,*RAC2*,*APOD*,*HPSE*,*RASGRP1*,***IFNG***,*VNN1*,*THBS2*,*ANGPT2*,*DPP4*,*EGR1*,*PTPRC*,*ST6GAL1*,*S100P*,*VAV3*,*AIMP1*,*MAGI1*,*IGFALS*,*DOCK8*,*NR4A3*,*SLC7A11*,*CD84*,***TNFAIP6***,*MYO10*,*CD55*,*CORO1A*,*CAMK4*,*IL20RB*,*CXCL13*,*VCAN*,*XCL1*,*HABP2*
  GOTERM_BP_FAT   Negative regulation of response to stimulus                            39      1.91E‐04     *NKD2*,*NRP1*,*IL19*,*TMEM161A*,***FASLG***,*IRAK3*,*CD96*,*NPHP4*,*APOD*,*CHST11*,*INPP5F*,*VNN1*,*CALCRL*,*ANGPT2*,*F11*,*ZFP36*,*EGR1*,*PTPRC*,*ST6GAL1*,*SOCS3*,*NR4A3*,*RGS14*,*PRKCB*,*PLAUR*,*SOD2*,*CD84*,*DUSP5*,***TNFAIP6***,*CD55*,*RGS1*,*DKK1*,*THBD*,*IL20RB*,*ADM*,*CXCL13*,*HELB*,*IGFBP1*,*XCL1*,*DUSP6*
  GOTERM_BP_FAT   Negative regulation of response to external stimulus                   14      1.97E‐04     *ZFP36*,*F11*,*ST6GAL1*,*NRP1*,*SOCS3*,*PLAUR*,***TNFAIP6***,*THBD*,*IL20RB*,*APOD*,*CXCL13*,*INPP5F*,*CALCRL*,*ANGPT2*
  GOTERM_MF_FAT   Serine‐type endopeptidase activity                                     13      2.08E‐04     *F11*,*MMP10*,*CFB*,***GZMA***,*C1RL*,*MMP7*,***GZMB***,*CFI*,*C1S*,*DPP4*,*MMP1*,*TMPRSS3*,*HABP2*
  GOTERM_BP_FAT   Chemotaxis                                                             21      2.57E‐04     *FGF18*,*ST6GAL1*,*NRP1*,*VAV3*,*AIMP1*,*KIF5A*,*CCR1*,*CXCL2*,*NR4A1*,*NR4A3*,*CCL4*,*PLAUR*,*CORO1A*,*RAC2*,*CXCL13*,***IFNG***,*CMTM7*,*TREM1*,*LBP*,*XCL1*,*ANGPT2*
  GOTERM_BP_FAT   Neutrophil chemotaxis                                                  8       2.61E‐04     *VAV3*,*RAC2*,*CXCL2*,***IFNG***,*TREM1*,*LBP*,*XCL1*,*CCL4*
  GOTERM_BP_FAT   Taxis                                                                  21      2.62E‐04     *FGF18*,*ST6GAL1*,*NRP1*,*VAV3*,*AIMP1*,*KIF5A*,*CCR1*,*CXCL2*,*NR4A1*,*NR4A3*,*CCL4*,*PLAUR*,*CORO1A*,*RAC2*,*CXCL13*,***IFNG***,*CMTM7*,*TREM1*,*LBP*,*XCL1*,*ANGPT2*
  GOTERM_BP_FAT   Regulation of cell--cell adhesion                                      17      2.64E‐04     *PTPRC*,*ASS1*,*NR4A3*,*ZEB1*,*CORO1A*,*CD55*,*MYO10*,*CDKN2A*,*RAC2*,*CAMK4*,*IL20RB*,*CXCL13*,*RASGRP1*,***IFNG***,*VNN1*,*XCL1*,*DPP4*
  GOTERM_BP_FAT   Regulation of apoptotic process                                        39      2.88E‐04     *FGFR2*,*NRP1*,*IL19*,*TMEM161A*,***FASLG***,*AURKB*,*SFN*,*PMAIP1*,*CDKN2A*,*MYOCD*,***IFNG***,*CHST11*,*ROBO4*,*VNN1*,*PHLDA1*,*ZFP36*,*EGR1*,*ST6GAL1*,*IL2RB*,*VAV3*,*SOCS3*,***GZMA***,*BCL2A1*,*PIM1*,*NR4A1*,***GZMB***,*DOCK8*,*NR4A3*,*ANXA4*,*PLAUR*,*PLAC8*,*SOD2*,*CD38*,*CORO1A*,*ADM*,*SIX1*,*LGALS14*,*TNFAIP8*,*DUSP6*
  GOTERM_BP_FAT   Cell killing                                                           9       2.90E‐04     *PTPRC*,*CORO1A*,*RASGRP1*,*GNLY*,***IFNG***,***GZMB***,*TREM1*,*XCL1*,*KIR3DL1*
  GOTERM_BP_FAT   Regulation of leukocyte cell--cell adhesion                            15      2.95E‐04     *PTPRC*,*ASS1*,*NR4A3*,*ZEB1*,*CORO1A*,*CD55*,*CDKN2A*,*RAC2*,*CAMK4*,*IL20RB*,*RASGRP1*,***IFNG***,*VNN1*,*XCL1*,*DPP4*
  GOTERM_BP_FAT   Natural killer cell mediated immunity                                  7       3.01E‐04     *CD96*,*KLRC2*,*CORO1A*,*RASGRP1*,***GZMB***,*KLRD1*,*KIR3DL1*
  GOTERM_BP_FAT   Regulation of programmed cell death                                    39      3.49E‐04     *FGFR2*,*NRP1*,*IL19*,*TMEM161A*,***FASLG***,*AURKB*,*SFN*,*PMAIP1*,*CDKN2A*,*MYOCD*,***IFNG***,*CHST11*,*ROBO4*,*VNN1*,*PHLDA1*,*ZFP36*,*EGR1*,*ST6GAL1*,*IL2RB*,*VAV3*,*SOCS3*,***GZMA***,*BCL2A1*,*PIM1*,*NR4A1*,***GZMB***,*DOCK8*,*NR4A3*,*ANXA4*,*PLAUR*,*PLAC8*,*SOD2*,*CD38*,*CORO1A*,*ADM*,*SIX1*,*LGALS14*,*TNFAIP8*,*DUSP6*
  GOTERM_BP_FAT   Cell death                                                             49      3.99E‐04     *FGFR2*,*PRF1*,*NRP1*,*IL19*,*TMEM161A*,***FASLG***,*PMAIP1*,*AURKB*,*SFN*,*CDKN2A*,*MYOCD*,***IFNG***,*CHST11*,*ROBO4*,*VNN1*,*MX1*,*SRGN*,*PHLDA1*,*EGR1*,*ZFP36*,*ST6GAL1*,*IL2RB*,*VAV3*,*MAGI1*,*AIMP1*,*SOCS3*,***GZMA***,*BCL2A1*,*PIM1*,*NR4A1*,***GZMB***,*NR4A3*,*DOCK8*,*ANXA4*,*PLAC8*,*SOD2*,*PLAUR*,*PRKCB*,*CD38*,*CORO1A*,*ADM*,*SIX1*,*LGALS14*,*TNFAIP8*,*HIF3A*,*EMP1*,*HTR2A*,*DUSP6*,*PRODH*
  GOTERM_BP_FAT   Regulation of T cell differentiation in thymus                         5       5.38E‐04     *CDKN2A*,*CAMK4*,*RASGRP1*,*VNN1*,*ZEB1*
  GOTERM_BP_FAT   Regulation of thymocyte aggregation                                    5       5.38E‐04     *CDKN2A*,*CAMK4*,*RASGRP1*,*VNN1*,*ZEB1*
  GOTERM_BP_FAT   Positive regulation of chemotaxis                                      9       5.69E‐04     *FGF18*,*NRP1*,*RAC2*,*CXCL13*,*CCR1*,*CXCL2*,*LBP*,*XCL1*,*CCL4*
  GOTERM_BP_FAT   Regulation of chemotaxis                                               11      5.84E‐04     *FGF18*,*ST6GAL1*,*NRP1*,*RAC2*,*CXCL13*,*CCR1*,*CXCL2*,*LBP*,*XCL1*,*ANGPT2*,*CCL4*
  GOTERM_BP_FAT   Neutrophil migration                                                   8       5.86E‐04     *VAV3*,*RAC2*,*CXCL2*,***IFNG***,*TREM1*,*LBP*,*XCL1*,*CCL4*
  GOTERM_BP_FAT   Humoral immune response                                                12      6.16E‐04     *CD55*,*ST6GAL1*,*ADM*,*CFB*,*RNASE7*,***IFNG***,*C1RL*,*CFI*,*C1S*,*TREM1*,*TRDC*,*BLNK*
  GOTERM_BP_FAT   Leukocyte chemotaxis                                                   11      6.34E‐04     *CORO1A*,*VAV3*,*RAC2*,*CXCL13*,*CCR1*,*CXCL2*,***IFNG***,*TREM1*,*LBP*,*XCL1*,*CCL4*
  GOTERM_BP_FAT   Regulation of cell death                                               40      6.46E‐04     *FGFR2*,*NRP1*,*IL19*,*TMEM161A*,***FASLG***,*AURKB*,*SFN*,*PMAIP1*,*CDKN2A*,*MYOCD*,***IFNG***,*CHST11*,*ROBO4*,*VNN1*,*PHLDA1*,*ZFP36*,*EGR1*,*ST6GAL1*,*IL2RB*,*VAV3*,*SOCS3*,***GZMA***,*BCL2A1*,*PIM1*,*NR4A1*,***GZMB***,*DOCK8*,*NR4A3*,*ANXA4*,*PLAUR*,*PLAC8*,*SOD2*,*CD38*,*CORO1A*,*ADM*,*SIX1*,*LGALS14*,*TNFAIP8*,*DUSP6*,*PRODH*
  GOTERM_BP_FAT   Negative regulation of apoptotic process                               26      6.57E‐04     *FGFR2*,*NRP1*,*IL19*,*TMEM161A*,***FASLG***,*AURKB*,*SFN*,*MYOCD*,*CHST11*,*VNN1*,*ST6GAL1*,*IL2RB*,*SOCS3*,*BCL2A1*,*PIM1*,*NR4A1*,*NR4A3*,*DOCK8*,*ANXA4*,*SOD2*,*PLAC8*,*PLAUR*,*CD38*,*CORO1A*,*SIX1*,*TNFAIP8*
  GOTERM_BP_FAT   Innate immune response                                                 26      6.99E‐04     *KLRC2*,*ASS1*,*TRDC*,*C1S*,*CCL4*,*CD96*,*IRAK3*,*RASGRP1*,*RNASE7*,***IFNG***,*VNN1*,*CFI*,*LBP*,*MX1*,*KLRD1*,*EGR1*,*CFB*,*SOCS3*,***GZMB***,*CD84*,*CORO1A*,*CD55*,*C1RL*,*TREM1*,*XCL1*,*KIR3DL1*
  GOTERM_BP_FAT   Glycosaminoglycan metabolic process                                    10      7.21E‐04     *ARSB*,*CHSY3*,*HPSE*,*CHST6*,*B3GNT7*,*CHST11*,*PIM1*,*HSPG2*,*VCAN*,*HS2ST1*
  GOTERM_BP_FAT   Programmed cell death                                                  46      7.29E‐04     *FGFR2*,*PRF1*,*NRP1*,*IL19*,*TMEM161A*,***FASLG***,*AURKB*,*SFN*,*PMAIP1*,*CDKN2A*,*MYOCD*,***IFNG***,*CHST11*,*ROBO4*,*VNN1*,*MX1*,*SRGN*,*PHLDA1*,*ZFP36*,*EGR1*,*ST6GAL1*,*IL2RB*,*VAV3*,*AIMP1*,*SOCS3*,***GZMA***,*BCL2A1*,*PIM1*,*NR4A1*,***GZMB***,*DOCK8*,*NR4A3*,*ANXA4*,*PRKCB*,*PLAUR*,*PLAC8*,*SOD2*,*CD38*,*CORO1A*,*ADM*,*SIX1*,*LGALS14*,*TNFAIP8*,*HIF3A*,*DUSP6*,*PRODH*
  GOTERM_BP_FAT   Apoptotic process                                                      44      7.55E‐04     *FGFR2*,*PRF1*,*NRP1*,*IL19*,*TMEM161A*,***FASLG***,*AURKB*,*SFN*,*PMAIP1*,*CDKN2A*,*MYOCD*,***IFNG***,*CHST11*,*VNN1*,*MX1*,*SRGN*,*PHLDA1*,*ZFP36*,*ST6GAL1*,*IL2RB*,*VAV3*,*AIMP1*,*SOCS3*,***GZMA***,*BCL2A1*,*PIM1*,*NR4A1*,***GZMB***,*DOCK8*,*NR4A3*,*ANXA4*,*PRKCB*,*PLAUR*,*PLAC8*,*SOD2*,*CD38*,*CORO1A*,*ADM*,*SIX1*,*LGALS14*,*TNFAIP8*,*HIF3A*,*DUSP6*,*PRODH*
  GOTERM_BP_FAT   Negative regulation of programmed cell death                           26      7.88E‐04     *FGFR2*,*NRP1*,*IL19*,*TMEM161A*,***FASLG***,*AURKB*,*SFN*,*MYOCD*,*CHST11*,*VNN1*,*ST6GAL1*,*IL2RB*,*SOCS3*,*BCL2A1*,*PIM1*,*NR4A1*,*NR4A3*,*DOCK8*,*ANXA4*,*SOD2*,*PLAC8*,*PLAUR*,*CD38*,*CORO1A*,*SIX1*,*TNFAIP8*
  GOTERM_BP_FAT   Granulocyte chemotaxis                                                 8       8.39E‐04     *VAV3*,*RAC2*,*CXCL2*,***IFNG***,*TREM1*,*LBP*,*XCL1*,*CCL4*
  GOTERM_BP_FAT   Cytokine production involved in immune response                        7       8.41E‐04     *IRAK3*,*CD96*,*CD55*,*CAMK4*,*NR4A3*,*TREM1*,*XCL1*
  GOTERM_BP_FAT   Positive regulation of immune system process                           28      8.58E‐04     *RBP4*,*PTPRC*,*VAV3*,*CFB*,*CCR1*,*CXCL2*,*C1S*,*TRDC*,*NR4A3*,*CCL4*,*PRKCB*,*CD84*,*FOS*,*IRAK3*,*CD38*,*CD55*,*MYO10*,*CORO1A*,*RAC2*,*CXCL13*,*RASGRP1*,***IFNG***,*C1RL*,*VNN1*,*LBP*,*CFI*,*XCL1*,*DPP4*
  GOTERM_BP_FAT   Leukocyte apoptotic process                                            8       8.88E‐04     *ST6GAL1*,*CDKN2A*,*LGALS14*,***IFNG***,***FASLG***,*NR4A3*,*DOCK8*,*AURKB*
  GOTERM_BP_FAT   Production of molecular mediator of immune response                    10      .001012913   *PTPRC*,*IRAK3*,*CD96*,*RBP4*,*CD55*,*CAMK4*,***IFNG***,*NR4A3*,*TREM1*,*XCL1*
  GOTERM_BP_FAT   Regulation of mononuclear cell proliferation                           11      .001040266   *PTPRC*,*CD38*,*CD55*,*ST6GAL1*,*CORO1A*,*VAV3*,*CDKN2A*,*RAC2*,*IL20RB*,***IFNG***,*XCL1*
  GOTERM_BP_FAT   Aminoglycan metabolic process                                          10      .001061591   *ARSB*,*CHSY3*,*HPSE*,*CHST6*,*B3GNT7*,*CHST11*,*PIM1*,*HSPG2*,*VCAN*,*HS2ST1*
  GOTERM_BP_FAT   Response to bacterium                                                  20      .001085717   *ZFP36*,*ASS1*,*SOCS3*,*GNLY*,*CXCL2*,*STATH*,***FASLG***,*TRDC*,*SOD2*,*PLAC8*,*CD96*,*IRAK3*,*FOS*,*THBD*,*ADM*,*CXCL13*,*RNASE7*,***IFNG***,*TREM1*,*LBP*
  GOTERM_BP_FAT   Leukocyte cell--cell adhesion                                          18      .001187931   *EGR1*,*PTPRC*,*ASS1*,*LEPR*,*NR4A3*,*ZEB1*,*DOCK8*,*CORO1A*,*CD55*,*CDKN2A*,*RAC2*,*CAMK4*,*IL20RB*,*RASGRP1*,***IFNG***,*VNN1*,*XCL1*,*DPP4*
  GOTERM_MF_FAT   Glycosaminoglycan binding                                              11      .001232209   *FGFR2*,*F11*,***TNFAIP6***,*NRP1*,*CXCL13*,*RNASE7*,*MMP7*,*COL25A1*,*VCAN*,*THBS2*,*HABP2*
  GOTERM_BP_FAT   Leukocyte aggregation                                                  17      .001364809   *EGR1*,*PTPRC*,*LEPR*,*NR4A3*,*ZEB1*,*DOCK8*,*CORO1A*,*CD55*,*CDKN2A*,*RAC2*,*CAMK4*,*IL20RB*,*RASGRP1*,***IFNG***,*VNN1*,*XCL1*,*DPP4*
  GOTERM_BP_FAT   Regulation of lymphocyte activation                                    16      .001403667   *PTPRC*,*VAV3*,*TRDC*,*ZEB1*,*CD38*,*CORO1A*,*CD55*,*CDKN2A*,*RAC2*,*CAMK4*,*IL20RB*,*RASGRP1*,***IFNG***,*VNN1*,*XCL1*,*DPP4*
  GOTERM_BP_FAT   Regulation of leukocyte proliferation                                  11      .00143279    *PTPRC*,*CD38*,*CD55*,*ST6GAL1*,*CORO1A*,*VAV3*,*CDKN2A*,*RAC2*,*IL20RB*,***IFNG***,*XCL1*
  GOTERM_BP_FAT   Leukocyte mediated cytotoxicity                                        7       .001521044   *PTPRC*,*CORO1A*,*RASGRP1*,***GZMB***,*TREM1*,*XCL1*,*KIR3DL1*
  GOTERM_BP_FAT   Positive regulation of leukocyte chemotaxis                            7       .001521044   *RAC2*,*CXCL13*,*CCR1*,*CXCL2*,*LBP*,*XCL1*,*CCL4*
  GOTERM_BP_FAT   Response to lipopolysaccharide                                         14      .001525141   *ZFP36*,*IRAK3*,*CD96*,*FOS*,*THBD*,*ADM*,*ASS1*,*SOCS3*,*CXCL13*,*CXCL2*,***IFNG***,***FASLG***,*LBP*,*SOD2*
  GOTERM_BP_FAT   Granulocyte migration                                                  8       .001597708   *VAV3*,*RAC2*,*CXCL2*,***IFNG***,*TREM1*,*LBP*,*XCL1*,*CCL4*
  GOTERM_BP_FAT   Response to lipid                                                      27      .001721042   *RBP4*,*THRB*,*ASS1*,*RBP1*,*CXCL2*,*TMEM161A*,***FASLG***,*CD96*,*IRAK3*,*FOS*,***IFNG***,*LBP*,*NR2F1*,*ZFP36*,*SOCS3*,*PIM1*,*NR4A1*,*FOSB*,*NR4A3*,*SOD2*,*CD38*,*SSTR2*,*THBD*,*DKK1*,*ADM*,*CXCL13*,*FABP3*
  GOTERM_BP_FAT   Response to drug                                                       17      .001755254   *SLC8A1*,*VAV3*,*ASS1*,*CYP2B6*,*CYP2C9*,*SOCS3*,*FOSB*,*CCL4*,*SOD2*,*CD38*,*FOS*,*APOD*,*CD69*,***IFNG***,*FABP3*,*HTR2A*,*DUSP6*
  GOTERM_BP_FAT   Regulation of cell adhesion                                            21      .001839233   *PTPRC*,*ST6GAL1*,*VAV3*,*ASS1*,*ZEB1*,*NR4A3*,*CORO1A*,*CD55*,*MYO10*,*CDKN2A*,*RAC2*,*CAMK4*,*IL20RB*,*APOD*,*CXCL13*,*RASGRP1*,***IFNG***,*VNN1*,*XCL1*,*ANGPT2*,*DPP4*
  GOTERM_BP_FAT   Regulation of T cell activation                                        13      .001997259   *PTPRC*,*ZEB1*,*CORO1A*,*CD55*,*CDKN2A*,*RAC2*,*IL20RB*,*CAMK4*,*RASGRP1*,***IFNG***,*VNN1*,*XCL1*,*DPP4*
  GOTERM_BP_FAT   Negative regulation of cytokine production                             11      .002001253   *CD84*,*ZFP36*,*IRAK3*,*CD96*,*APOD*,*IL20RB*,***IFNG***,*LBP*,*XCL1*,*ANXA4*,*SRGN*
  GOTERM_BP_FAT   Cellular defense response                                              6       .002050165   *PRF1*,*KLRC2*,*GNLY*,*LBP*,*KIR2DL4*,*KIR3DL2*
  GOTERM_BP_FAT   Inflammatory cell apoptotic process                                    4       .002205885   *ST6GAL1*,*CDKN2A*,***IFNG***,***FASLG***
  GOTERM_BP_FAT   Response to molecule of bacterial origin                               14      .002213254   *ZFP36*,*IRAK3*,*CD96*,*FOS*,*THBD*,*ADM*,*ASS1*,*SOCS3*,*CXCL13*,*CXCL2*,***IFNG***,***FASLG***,*LBP*,*SOD2*
  GOTERM_BP_FAT   Negative regulation of cell death                                      26      .00245476    *FGFR2*,*NRP1*,*IL19*,*TMEM161A*,***FASLG***,*AURKB*,*SFN*,*MYOCD*,*CHST11*,*VNN1*,*ST6GAL1*,*IL2RB*,*SOCS3*,*BCL2A1*,*PIM1*,*NR4A1*,*NR4A3*,*DOCK8*,*ANXA4*,*SOD2*,*PLAC8*,*PLAUR*,*CD38*,*CORO1A*,*SIX1*,*TNFAIP8*
  GOTERM_BP_FAT   Mononuclear cell proliferation                                         12      .002460795   *PTPRC*,*CD38*,*CD55*,*ST6GAL1*,*CORO1A*,*VAV3*,*CDKN2A*,*RAC2*,*IL20RB*,***IFNG***,*DOCK8*,*XCL1*
  GOTERM_BP_FAT   Response to wounding                                                   21      .002508224   *ZFP36*,*F11*,*NRP1*,*VAV3*,*AIMP1*,*CCR1*,*DOCK8*,*SLC7A11*,*PRKCB*,*PLAUR*,*SOD2*,*THBD*,*RAC2*,*APOD*,*ADM*,*HPSE*,*INPP5F*,*H3F3B*,*IGFBP1*,*PAPSS2*,*FABP5*
  GOTERM_BP_FAT   Positive regulation of cell proliferation                              25      .002576078   *FGFR2*,*FGF18*,*NRP1*,***FASLG***,*RAC2*,*MYOCD*,*HPSE*,***IFNG***,*CALCRL*,*DPP4*,*EGR1*,*PTPRC*,*ST6GAL1*,*VAV3*,*NR4A1*,*NR4A3*,*PLAC8*,*CD38*,*CORO1A*,*CD55*,*ADM*,*SIX1*,*ID4*,*XCL1*,*HTR2A*
  GOTERM_BP_FAT   Myeloid leukocyte migration                                            9       .002633977   *VAV3*,*RAC2*,*CCR1*,*CXCL2*,***IFNG***,*TREM1*,*LBP*,*XCL1*,*CCL4*
  GOTERM_BP_FAT   Positive regulation of leukocyte activation                            13      .002679897   *PTPRC*,*CD38*,*CD55*,*CORO1A*,*VAV3*,*RASGRP1*,***IFNG***,*VNN1*,*LBP*,*NR4A3*,*TRDC*,*XCL1*,*DPP4*
  GOTERM_BP_FAT   Response to extracellular stimulus                                     17      .002734588   *ZFP36*,*ARSB*,*SLC8A1*,*ASS1*,*RBP1*,*SOCS3*,*PIM1*,*MMP7*,*GAST*,*PMAIP1*,*SOD2*,*FOS*,*SSTR2*,*MYOCD*,*ADM*,*SLC2A1*,*CP*
  GOTERM_BP_FAT   Multi--multicellular organism process                                  11      .002740849   *CD38*,*FOS*,*CD55*,*PSG9*,*THBD*,*ADM*,*MMP7*,*H3F3B*,*SLC38A1*,*FOSB*,*ANGPT2*
  GOTERM_BP_FAT   Regulation of inflammatory response                                    13      .002812705   *ZFP36*,***TNFAIP6***,*CD55*,*APOD*,*IL20RB*,*SOCS3*,*CFB*,*SLC7A2*,*CFI*,*CALCRL*,*LBP*,*XCL1*,*CCL4*
  GOTERM_BP_FAT   Single organismal cell--cell adhesion                                  22      .002886539   *EGR1*,*PTPRC*,*ASS1*,*LEPR*,*DOCK8*,*NR4A3*,*ZEB1*,*SLC7A11*,*NPHP4*,*CORO1A*,*CD55*,*MYO10*,*CDKN2A*,*RAC2*,*CAMK4*,*IL20RB*,*CXCL13*,*RASGRP1*,***IFNG***,*VNN1*,*XCL1*,*DPP4*
  GOTERM_CC_FAT   Cell surface                                                           24      .002962228   *PPFIA2*,*ARSB*,*FGFR2*,*PTPRC*,*IL2RB*,*NRP1*,*TRPM8*,*AIMP1*,*CCR1*,*MMP7*,***FASLG***,*TRDC*,*ANXA4*,*SLC7A11*,*PROM1*,*CD38*,*CD55*,*THBD*,*CD69*,***IFNG***,*LBP*,*DPP6*,*KLRD1*,*DPP4*
  GOTERM_BP_FAT   T cell aggregation                                                     16      .002988034   *EGR1*,*PTPRC*,*LEPR*,*ZEB1*,*DOCK8*,*CORO1A*,*CD55*,*CDKN2A*,*RAC2*,*CAMK4*,*IL20RB*,*RASGRP1*,***IFNG***,*VNN1*,*XCL1*,*DPP4*
  GOTERM_BP_FAT   T cell activation                                                      16      .002988034   *EGR1*,*PTPRC*,*LEPR*,*ZEB1*,*DOCK8*,*CORO1A*,*CD55*,*CDKN2A*,*RAC2*,*CAMK4*,*IL20RB*,*RASGRP1*,***IFNG***,*VNN1*,*XCL1*,*DPP4*
  GOTERM_BP_FAT   Lymphocyte aggregation                                                 16      .003046718   *EGR1*,*PTPRC*,*LEPR*,*ZEB1*,*DOCK8*,*CORO1A*,*CD55*,*CDKN2A*,*RAC2*,*CAMK4*,*IL20RB*,*RASGRP1*,***IFNG***,*VNN1*,*XCL1*,*DPP4*
  GOTERM_BP_FAT   Cellular modified amino acid metabolic process                         9       .003065973   *CHDH*,*MTHFD2*,*MTHFS*,*GSTT2B*,*ASS1*,*SLCO4A1*,*MTHFD1L*,*PRODH*,*SOD2*
  GOTERM_BP_FAT   Negative regulation of protein serine/threonine kinase activity        8       .003199245   *DUSP5*,*IRAK3*,*CDKN2A*,*MYOCD*,*PKIB*,*SFN*,*RGS14*,*DUSP6*
  GOTERM_BP_FAT   Positive regulation of cell migration                                  15      .003220579   *PTPRC*,***TNFAIP6***,*FGF18*,*SLC8A1*,*CORO1A*,*NRP1*,*RAC2*,*CXCL13*,*CCR1*,*CXCL2*,***IFNG***,*DOCK7*,*LBP*,*XCL1*,*CCL4*
  GOTERM_BP_FAT   Aging                                                                  13      .003269145   *ASS1*,*SOCS3*,*BCL2A1*,*MMP7*,*AURKB*,*SOD2*,*FOS*,*CDKN2A*,*APOD*,*ADM*,*IGFBP1*,*CP*,*HTR2A*
  GOTERM_BP_FAT   Positive regulation of cell activation                                 13      .003376692   *PTPRC*,*CD38*,*CD55*,*CORO1A*,*VAV3*,*RASGRP1*,***IFNG***,*VNN1*,*LBP*,*NR4A3*,*TRDC*,*XCL1*,*DPP4*
  GOTERM_BP_FAT   Female pregnancy                                                       10      .003499079   *CD38*,*FOS*,*PSG9*,*THBD*,*ADM*,*MMP7*,*H3F3B*,*SLC38A1*,*FOSB*,*ANGPT2*
  GOTERM_BP_FAT   Regulation of lymphocyte proliferation                                 10      .003499079   *PTPRC*,*CD38*,*CD55*,*CORO1A*,*VAV3*,*CDKN2A*,*RAC2*,*IL20RB*,***IFNG***,*XCL1*
  GOTERM_BP_FAT   Leukocyte proliferation                                                12      .003703152   *PTPRC*,*CD38*,*CD55*,*ST6GAL1*,*CORO1A*,*VAV3*,*CDKN2A*,*RAC2*,*IL20RB*,***IFNG***,*DOCK8*,*XCL1*
  GOTERM_BP_FAT   Defense response to other organism                                     19      .003727248   *PRF1*,*PTPRC*,*DPF3*,*AIMP1*,*GNLY*,*STATH*,*LMCD1*,*TRDC*,*PMAIP1*,*COTL1*,*PLAC8*,*ADM*,*CXCL13*,*RNASE7*,***IFNG***,*TREM1*,*LBP*,*MX1*,*FCGR3B*
  GOTERM_BP_FAT   Regulation of leukocyte chemotaxis                                     7       .004046973   *RAC2*,*CXCL13*,*CCR1*,*CXCL2*,*LBP*,*XCL1*,*CCL4*
  GOTERM_BP_FAT   Negative regulation of immune effector process                         7       .004245428   *CD84*,*PTPRC*,*IRAK3*,*CD96*,*CD55*,*IL20RB*,*XCL1*
  GOTERM_BP_FAT   Positive regulation of mononuclear cell proliferation                  8       .00427214    *PTPRC*,*CD38*,*CD55*,*ST6GAL1*,*CORO1A*,*VAV3*,***IFNG***,*XCL1*
  GOTERM_BP_FAT   Positive regulation of cell motility                                   15      .004330368   *PTPRC*,***TNFAIP6***,*FGF18*,*SLC8A1*,*CORO1A*,*NRP1*,*RAC2*,*CXCL13*,*CCR1*,*CXCL2*,***IFNG***,*DOCK7*,*LBP*,*XCL1*,*CCL4*
  GOTERM_BP_FAT   Positive regulation of cell--cell adhesion                             11      .004408001   *PTPRC*,*CD55*,*MYO10*,*CORO1A*,*CXCL13*,*RASGRP1*,***IFNG***,*VNN1*,*NR4A3*,*XCL1*,*DPP4*
  GOTERM_BP_FAT   Response to cold                                                       5       .00466463    *FOS*,*ADM*,*TRPM8*,*PLAC8*,*SOD2*
  GOTERM_BP_FAT   Positive regulation of neutrophil chemotaxis                           4       .005125974   *RAC2*,*CXCL2*,*LBP*,*XCL1*
  GOTERM_MF_FAT   Aminopeptidase activity                                                5       .005195241   *F11*,*METAP1D*,*PHEX*,*DPP6*,*DPP4*
  GOTERM_BP_FAT   Positive regulation of leukocyte proliferation                         8       .00539139    *PTPRC*,*CD38*,*CD55*,*ST6GAL1*,*CORO1A*,*VAV3*,***IFNG***,*XCL1*
  GOTERM_BP_FAT   Negative regulation of leukocyte mediated immunity                     5       .005435985   *CD84*,*PTPRC*,*CD96*,*IL20RB*,*XCL1*
  GOTERM_BP_FAT   Positive regulation of cellular component movement                     15      .005527572   *PTPRC*,***TNFAIP6***,*FGF18*,*SLC8A1*,*CORO1A*,*NRP1*,*RAC2*,*CXCL13*,*CCR1*,*CXCL2*,***IFNG***,*DOCK7*,*LBP*,*XCL1*,*CCL4*
  GOTERM_BP_FAT   Positive regulation of locomotion                                      15      .005622113   *PTPRC*,***TNFAIP6***,*FGF18*,*SLC8A1*,*CORO1A*,*NRP1*,*RAC2*,*CXCL13*,*CCR1*,*CXCL2*,***IFNG***,*DOCK7*,*LBP*,*XCL1*,*CCL4*
  GOTERM_BP_FAT   Endothelial cell chemotaxis                                            4       .005762154   *FGF18*,*NRP1*,*CXCL13*,*NR4A1*
  GOTERM_BP_FAT   Myeloid leukocyte mediated immunity                                    6       .005944619   *CD84*,*RAC2*,*CAMK4*,*RASGRP1*,*NR4A3*,*TREM1*
  GOTERM_BP_FAT   Renal system vasculature development                                   4       .006443547   *EGR1*,*NRP1*,***IFNG***,*ANGPT2*
  GOTERM_BP_FAT   Kidney vasculature development                                         4       .006443547   *EGR1*,*NRP1*,***IFNG***,*ANGPT2*
  GOTERM_BP_FAT   Single organism cell adhesion                                          22      .006492015   *EGR1*,*PTPRC*,*ASS1*,*LEPR*,*DOCK8*,*NR4A3*,*ZEB1*,*SLC7A11*,*NPHP4*,*CORO1A*,*CD55*,*MYO10*,*CDKN2A*,*RAC2*,*CAMK4*,*IL20RB*,*CXCL13*,*RASGRP1*,***IFNG***,*VNN1*,*XCL1*,*DPP4*
  GOTERM_BP_FAT   Regulation of locomotion                                               22      .006605694   *ARSB*,*PTPRC*,*FGF18*,*SLC8A1*,*ST6GAL1*,*NRP1*,*CCR1*,*CXCL2*,*DOCK7*,*CCL4*,***TNFAIP6***,*MMP10*,*CORO1A*,*RAC2*,*APOD*,*CXCL13*,***IFNG***,*ROBO4*,*INPP5F*,*LBP*,*XCL1*,*ANGPT2*
  GOTERM_BP_FAT   Glycosaminoglycan biosynthetic process                                 7       .006645161   *CHSY3*,*CHST6*,*B3GNT7*,*CHST11*,*HSPG2*,*VCAN*,*HS2ST1*
  GOTERM_BP_FAT   Cytokine production                                                    19      .006800751   *ZFP36*,*EGR1*,*IL19*,*NR4A3*,*ANXA4*,*CD84*,*CD96*,*IRAK3*,*CD55*,*CAMK4*,*IL20RB*,*APOD*,*HPSE*,*RASGRP1*,***IFNG***,*TREM1*,*LBP*,*XCL1*,*SRGN*
  GOTERM_BP_FAT   Lymphocyte proliferation                                               11      .006835525   *PTPRC*,*CD38*,*CD55*,*CORO1A*,*VAV3*,*CDKN2A*,*RAC2*,*IL20RB*,***IFNG***,*DOCK8*,*XCL1*
  GOTERM_BP_FAT   Aminoglycan biosynthetic process                                       7       .006929937   *CHSY3*,*CHST6*,*B3GNT7*,*CHST11*,*HSPG2*,*VCAN*,*HS2ST1*
  GOTERM_BP_FAT   Mucopolysaccharide metabolic process                                   7       .006929937   *ARSB*,*CHSY3*,*CHST6*,*B3GNT7*,*CHST11*,*PIM1*,*VCAN*
  GOTERM_BP_FAT   Cellular response to chemical stimulus                                 56      .007101409   *FGF18*,*NRP1*,*THRB*,*LEPR*,*TMEM161A*,***FASLG***,*PMAIP1*,*ZEB1*,*FOS*,*MYOCD*,*CHST11*,***IFNG***,*VNN1*,*CALCRL*,*LBP*,*MX1*,*ANGPT2*,*CSF2RA*,*NR2F1*,*ZFP36*,*EGR1*,*SATB2*,*SOCS3*,*PIM1*,*FOSB*,*PRKCB*,*SSTR2*,*IL20RB*,*GUCY1B3*,*TREM1*,*PRODH*,*FGFR2*,*ASS1*,*CYP2B6*,*CCR1*,*CXCL2*,*CCL4*,*IRAK3*,*RAC2*,*CD69*,*UGT1A5*,*PTPRC*,*IL2RB*,*SLC8A1*,*VAV3*,*CYP2C9*,*NR4A1*,*NR4A3*,*SOD2*,*CORO1A*,*DKK1*,*CXCL13*,*HIF3A*,*IGFBP1*,*XCL1*,*DUSP6*
  GOTERM_BP_FAT   Positive regulation of granulocyte chemotaxis                          4       .007170933   *RAC2*,*CXCL2*,*LBP*,*XCL1*
  GOTERM_BP_FAT   Lymphocyte differentiation                                             12      .007197221   *EGR1*,*PTPRC*,*CDKN2A*,*CAMK4*,*IKZF1*,*LEPR*,*RASGRP1*,***IFNG***,*CMTM7*,*VNN1*,*ZEB1*,*BLNK*
  GOTERM_BP_FAT   Epithelial cell migration                                              10      .007524598   *ARSB*,*FGF18*,*NRP1*,*S100P*,*CXCL13*,***IFNG***,*FERMT1*,*NR4A1*,*ANGPT2*,*DPP4*
  GOTERM_BP_FAT   Positive regulation of leukocyte migration                             7       .00752586    *RAC2*,*CXCL13*,*CCR1*,*CXCL2*,*LBP*,*XCL1*,*CCL4*
  GOTERM_BP_FAT   Regulation of neutrophil chemotaxis                                    4       .007945027   *RAC2*,*CXCL2*,*LBP*,*XCL1*
  GOTERM_BP_FAT   Epithelium migration                                                   10      .008151142   *ARSB*,*FGF18*,*NRP1*,*S100P*,*CXCL13*,***IFNG***,*FERMT1*,*NR4A1*,*ANGPT2*,*DPP4*
  GOTERM_BP_FAT   Formation of primary germ layer                                        7       .008157921   *FGFR2*,*DUSP5*,*LAMB3*,*DKK1*,*ETS2*,*NR4A3*,*DUSP6*
  GOTERM_BP_FAT   Response to hypoxia                                                    12      .008231471   *EGR1*,*CD38*,*SLC8A1*,*ADM*,*MYOCD*,*SOCS3*,*HIF3A*,*PMAIP1*,*ANGPT2*,*DPP4*,*PRKCB*,*SOD2*
  GOTERM_BP_FAT   Regulation of cell migration                                           20      .008409748   *ARSB*,*PTPRC*,*FGF18*,*SLC8A1*,*NRP1*,*CCR1*,*CXCL2*,*DOCK7*,*CCL4*,***TNFAIP6***,*MMP10*,*CORO1A*,*RAC2*,*APOD*,*CXCL13*,***IFNG***,*ROBO4*,*LBP*,*XCL1*,*ANGPT2*
  GOTERM_BP_FAT   Regulation of cell motility                                            21      .008458009   *ARSB*,*PTPRC*,*FGF18*,*SLC8A1*,*NRP1*,*CCR1*,*CXCL2*,*DOCK7*,*CCL4*,***TNFAIP6***,*MMP10*,*CORO1A*,*RAC2*,*APOD*,*CXCL13*,***IFNG***,*ROBO4*,*INPP5F*,*LBP*,*XCL1*,*ANGPT2*
  GOTERM_BP_FAT   Regulation of leukocyte apoptotic process                              6       .008502574   *ST6GAL1*,*CDKN2A*,*LGALS14*,*NR4A3*,*DOCK8*,*AURKB*
  GOTERM_BP_FAT   Regulation of response to stress                                       33      .008516958   *DPF3*,*TMEM161A*,*PMAIP1*,*CCL4*,*CD96*,*IRAK3*,*CDKN2A*,*APOD*,*HPSE*,*RASGRP1*,***IFNG***,*INPP5F*,*VNN1*,*LBP*,*CFI*,*CALCRL*,*FCGR3B*,*ZFP36*,*F11*,*SOCS3*,*CFB*,*LMCD1*,*NR4A3*,*PLAUR*,*SOD2*,***TNFAIP6***,*CD55*,*THBD*,*IL20RB*,*HELB*,*SLC7A2*,*TREM1*,*XCL1*
  GOTERM_BP_FAT   Negative regulation of defense response                                8       .008555067   *ZFP36*,*IRAK3*,*CD96*,***TNFAIP6***,*APOD*,*IL20RB*,*SOCS3*,*CALCRL*
  GOTERM_BP_FAT   Ameboidal‐type cell migration                                          12      .008776187   *ARSB*,*ZFAND5*,*FGF18*,*SLC8A1*,*NRP1*,*S100P*,*CXCL13*,***IFNG***,*FERMT1*,*NR4A1*,*ANGPT2*,*DPP4*
  GOTERM_BP_FAT   Response to oxygen‐containing compound                                 36      .008811937   *RBP4*,*ASS1*,*CXCL2*,*TMEM161A*,***FASLG***,*ZEB1*,*FOS*,*CD96*,*IRAK3*,*APOD*,***IFNG***,*LBP*,*CALCRL*,*ANGPT2*,*EGR1*,*ZFP36*,*SLC8A1*,*ST6GAL1*,*SOCS3*,*PIM1*,*NR4A1*,*FOSB*,*NR4A3*,*PRKCB*,*SOD2*,*CD38*,*SSTR2*,*CD55*,*DKK1*,*THBD*,*ADM*,*CXCL13*,*FABP3*,*GUCY1B3*,*IGFBP1*,*HTR2A*
  GOTERM_BP_FAT   Response to nutrient levels                                            15      .008839745   *ZFP36*,*ARSB*,*SLC8A1*,*ASS1*,*RBP1*,*SOCS3*,*PIM1*,*MMP7*,*GAST*,*PMAIP1*,*SOD2*,*SSTR2*,*ADM*,*SLC2A1*,*CP*
  GOTERM_BP_FAT   Regulation of T cell proliferation                                     8       .008844981   *PTPRC*,*CD55*,*CORO1A*,*CDKN2A*,*RAC2*,*IL20RB*,***IFNG***,*XCL1*
  GOTERM_BP_FAT   Negative regulation of transcription from RNA polymerase II promoter   21      .00904159    *ZFP36*,*EGR1*,*FGFR2*,*SATB2*,*THRB*,*IKZF1*,*LMCD1*,***FASLG***,*FOSB*,*AURKB*,*NR4A3*,*ZEB1*,*DKK1*,*MYOCD*,*ETS2*,*SIX1*,***IFNG***,*ID4*,*BHLHE40*,*S100A1*,*NR2F1*
  GOTERM_BP_FAT   Apoptotic mitochondrial changes                                        7       .009176322   *CDKN2A*,*BCL2A1*,***GZMB***,*PMAIP1*,*SFN*,*SOD2*,*PLAUR*
  GOTERM_BP_FAT   Regulation of leukocyte mediated immunity                              8       .009445487   *CD84*,*PTPRC*,*CD96*,*RAC2*,*IL20RB*,*RASGRP1*,***IFNG***,*XCL1*
  GOTERM_BP_FAT   Tissue migration                                                       10      .009536961   *ARSB*,*FGF18*,*NRP1*,*S100P*,*CXCL13*,***IFNG***,*FERMT1*,*NR4A1*,*ANGPT2*,*DPP4*
  GOTERM_BP_FAT   Positive regulation of neutrophil migration                            4       .009635883   *RAC2*,*CXCL2*,*LBP*,*XCL1*
  GOTERM_BP_FAT   Urogenital system development                                          12      .00975718    *FGFR2*,*PROM1*,*EGR1*,*RBP4*,*NRP1*,*ASS1*,*MYOCD*,*SERPINB5*,*SIX1*,***IFNG***,*ID4*,*ANGPT2*
  GOTERM_BP_FAT   Negative regulation of protein kinase activity                         10      .009782435   *DUSP5*,*PTPRC*,*IRAK3*,*CDKN2A*,*MYOCD*,*SOCS3*,*PKIB*,*SFN*,*RGS14*,*DUSP6*
  GOTERM_BP_FAT   Extracellular matrix disassembly                                       6       .009801526   *MMP10*,*LAMB3*,*HSPG2*,*MMP7*,*DPP4*,*MMP1*
  GOTERM_BP_FAT   Fat cell differentiation                                               9       .00988103    *ZFP36*,*LAMB3*,*BBS9*,*NR4A1*,*ID4*,*NR4A3*,*PLAC8*,*HTR2A*,*SOD2*
  GOTERM_BP_FAT   Embryonic skeletal system development                                  7       .009903808   *FGFR2*,*RBP4*,*SATB2*,*SIX1*,*CHST11*,*ZEB1*,*MTHFD1L*

Bold denotes gene names which are picked up in the results and discussion.
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The KEGG pathways that were associated with these genes involved the pathways that were related to immunity, such as "natural killer cell mediated cytotoxicity," "complement and coagulation cascades," "antigen processing and presentation," "Graft‐versus‐host disease," and "allograft rejection" (Tables [3](#rmb212030-tbl-0003){ref-type="table-wrap"} and [S2](#rmb212030-sup-0002){ref-type="supplementary-material"}). These KEGG pathways also included *IFN‐*γ*, GZMB*, and *FASLG*.

###### 

Kyoto Encyclopedia of Genes and Genomes pathway analysis for the genes that were up‐regulated in the thin endometrium

  Term                                        Count   *P* value   Gene
  ------------------------------------------- ------- ----------- -------------------------------------------------------------------------------------------
  Natural killer cell‐mediated cytotoxicity   10      8.21E‐04    *PRF1*,*VAV3*,*RAC2*,***IFNG***,***FASLG***,***GZMB***,*FCGR3B*,*KLRD1*,*KIR2DL4*,*PRKCB*
  Complement and coagulation cascades         7       .00270751   *F11*,*CD55*,*THBD*,*CFB*,*CFI*,*C1S*,*PLAUR*
  Transcriptional misregulation in cancer     10      .00722048   *PROM1*,*NFKBIZ*,*IL2RB*,*UTY*,*SIX1*,*BCL2A1*,*GRIA3*,***GZMB***,*H3F3B*,*NR4A3*
  Antigen processing and presentation         6       .01912738   *KLRC2*,***IFNG***,*KLRD1*,*KIR3DL1*,*KIR2DL4*,*KIR3DL2*
  Jak‐STAT signaling pathway                  8       .02846128   *IL2RB*,*IL20RB*,*SOCS3*,*LEPR*,*IL19*,***IFNG***,*PIM1*,*CSF2RA*
  Graft‐versus‐host disease                   4       .02903814   *PRF1*,***IFNG***,***FASLG***,***GZMB***
  Allograft rejection                         4       .03900192   *PRF1*,***IFNG***,***FASLG***,***GZMB***
  Amphetamine addiction                       5       .04526534   *FOS*,*CAMK4*,*GRIA3*,*FOSB*,*PRKCB*
  p53 signaling pathway                       5       .04740558   *CDKN2A*,*SERPINB5*,*RRM2*,*PMAIP1*,*SFN*

Jak‐STAT, Janus kinase/signal transducers and activators of transcription. Bold denotes gene names which are picked up in the results and discussion.
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3.3. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway analyses for the down‐regulated genes in the thin endometrium {#rmb212030-sec-0013}
------------------------------------------------------------------------------------------------------------------------------------

The down‐regulated genes in the thin endometrium were related to metabolic processes, such as "small molecule catabolic process," "single‐organism catabolic process," "organic acid catabolic process," and "carboxylic acid catabolic process" (Tables [4](#rmb212030-tbl-0004){ref-type="table-wrap"} and [S3](#rmb212030-sup-0003){ref-type="supplementary-material"}). The GO terms included genes for carnitine palmitoyltransferase I (*CPT1*), 3‐hydroxy‐3‐methylglutaryl‐coenzyme A (CoA) synthase 2 (*HMGCS2*), and 3‐oxoacid CoA‐transferase 1 (*OXCT1*), which are known to play important roles in generating energy in cells and tissues.[13](#rmb212030-bib-0013){ref-type="ref"}, [14](#rmb212030-bib-0014){ref-type="ref"}, [15](#rmb212030-bib-0015){ref-type="ref"}

###### 

Gene ontology analysis for the genes that were down‐regulated in the thin endometrium

  Category        Term                                                                       Count   *P* value    Gene
  --------------- -------------------------------------------------------------------------- ------- ------------ --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  GOTERM_BP_FAT   Small molecule catabolic process                                           21      2.80E‐07     *NUDT16*,*ALDH6A1*,*ECI2*,*KYNU*,*SORD*,*BCKDHB*,*CYP26A1*,*ALDH3B2*,*HGD*,***CBR3***,*ACADL*,***CPT1A***,***OXCT1***,*FUT3*,*QPRT*,*GAD1*,*GPT2*,*PCCA*,*CROT*,*DCXR*,*XYLB*
  GOTERM_BP_FAT   Single‐organism catabolic process                                          33      1.44E‐06     ***XDH***,*KYNU*,*SORD*,***OXCT1***,*PDE1A*,*FUT3*,***IDH1***,*ENTPD3*,*PLCB1*,*GAD1*,*GPT2*,*NUDT16*,*ECI2*,*ALDH6A1*,*HERPUD1*,*PLD6*,*BCKDHB*,*HGD*,*ALDH3B2*,*CYP26A1*,*COL25A1*,***CBR3***,*COL5A3*,*ACADL*,***CPT1A***,*PLA2G4A*,*COL1A2*,*ACE2*,*QPRT*,*PCCA*,*DCXR*,*CROT*,*XYLB*
  GOTERM_BP_FAT   Organic acid catabolic process                                             16      1.58E‐06     *ALDH6A1*,*ECI2*,*KYNU*,*SORD*,*BCKDHB*,*CYP26A1*,*HGD*,*ACADL*,***CPT1A***,*QPRT*,*GAD1*,*GPT2*,*PCCA*,*CROT*,*DCXR*,*XYLB*
  GOTERM_BP_FAT   Carboxylic acid catabolic process                                          14      8.69E‐06     *ALDH6A1*,*ECI2*,*SORD*,*HGD*,*CYP26A1*,*ACADL*,***CPT1A***,*QPRT*,*GAD1*,*GPT2*,*PCCA*,*CROT*,*DCXR*,*XYLB*
  GOTERM_BP_FAT   Oxidation‐reduction process                                                33      3.78E‐05     ***XDH***,*TM7SF2*,*C15ORF48*,*PAM*,*STEAP4*,*CYP2J2*,*SORD*,*OPRK1*,***PPARG***,*DUOX1*,*FMO5*,***IDH1***,*NFATC4*,*SCD5*,*HHIP*,*ECI2*,*ALDH6A1*,*BCKDHB*,*HGD*,*ALDH3B2*,*CYP26A1*,*CYB5A*,***CBR3***,*ACADL*,***CPT1A***,*DHRS7*,*IYD*,*ACSM1*,*SQLE*,*GNAS*,*PHF8*,*CROT*,*DCXR*
  GOTERM_BP_FAT   Secretion                                                                  36      4.37E‐05     ***XDH***,*COPA*,*PAM*,*NAAA*,*OPRK1*,*PML*,*POSTN*,*TPD52*,*TLR6*,*TRH*,*KCNS3*,*CASP5*,*NOV*,*WNK4*,***OXCT1***,*SYN2*,*SYBU*,*CREB3L1*,*CHRNA6*,*GAD1*,*MAP2K6*,*ABCA12*,*TRPM4*,*ACTN1*,*GAL*,*ISL1*,*NLRP2*,*PCLO*,***CPT1A***,*PLA2G4A*,*CHGA*,*STXBP6*,*SYTL4*,*GNAS*,*CA2*,*CPB2*
  GOTERM_BP_FAT   Carboxylic acid metabolic process                                          29      6.36E‐05     *PAM*,*KYNU*,*CYP2J2*,*SORD*,***PPARG***,*AGMAT*,***IDH1***,*UGT8*,*SCD5*,*GAD1*,*GPT2*,*GGTA1P*,*ECI2*,*ALDH6A1*,*PDK4*,*BCKDHB*,*HGD*,*CYP26A1*,*CYB5A*,*ACADL*,***CPT1A***,*ACSM3*,*ACSM1*,*PLA2G4A*,*QPRT*,*PCCA*,*DCXR*,*CROT*,*XYLB*
  GOTERM_BP_FAT   Oxoacid metabolic process                                                  29      7.06E‐05     *PAM*,*KYNU*,*CYP2J2*,*SORD*,***PPARG***,*AGMAT*,***IDH1***,*UGT8*,*SCD5*,*GAD1*,*GPT2*,*GGTA1P*,*ECI2*,*ALDH6A1*,*PDK4*,*BCKDHB*,*HGD*,*CYP26A1*,*CYB5A*,*ACADL*,***CPT1A***,*ACSM3*,*ACSM1*,*PLA2G4A*,*QPRT*,*PCCA*,*DCXR*,*CROT*,*XYLB*
  GOTERM_BP_FAT   Peptide transport                                                          15      9.83E‐05     *TRPM4*,*SLC15A2*,*ISL1*,*GAL*,*TRH*,*PCLO*,***CPT1A***,*KCNS3*,*NOV*,***OXCT1***,*TAP2*,*SYBU*,*SYTL4*,*GNAS*,*CA2*
  GOTERM_BP_FAT   Transmembrane transport                                                    39      1.02E‐04     *C15ORF48*,*CALHM1*,*SLC39A14*,*SLC38A4*,*ATP1B1*,*MFSD3*,*SLC15A2*,*OPRK1*,*KCNIP4*,*KCNS3*,*SLC24A4*,*MCOLN3*,*ANK3*,*TAP2*,*WNK4*,*SLC25A48*,*TTYH2*,*SLC39A8*,*CHRNA6*,*SLC43A1*,*ANO10*,*ABCA12*,*TRPM4*,*TRPM6*,*ABCC13*,*CYB5A*,*GAL*,*ANKH*,*ABCG1*,***CPT1A***,*GJB2*,*SLC26A3*,*ATP6V0E2*,*ADAMTS8*,*CLIC5*,*KCNN3*,*SLC7A1*,*CA2*,*SLC46A2*
  GOTERM_BP_FAT   Ion transport                                                              42      1.10E‐04     *C15ORF48*,*CALHM1*,*SLC39A14*,*STEAP4*,*SLC38A4*,*ATP1B1*,*MFSD3*,*SLC15A2*,*OPRK1*,***PPARG***,*PML*,*TRH*,*KCNIP4*,*SEC14L1*,*KCNS3*,*SLC24A4*,*MCOLN3*,*ANK3*,*WNK4*,*TTYH2*,*SLC39A8*,*CHRNA6*,*SLC43A1*,*MAP2K6*,*ANO10*,*TRPM4*,*RAMP2*,*TRPM6*,*CYB5A*,*GAL*,*ANKH*,***CPT1A***,*SLC26A3*,*PLA2G4A*,*ATP6V0E2*,*ADAMTS8*,*PKP2*,*CLIC5*,*KCNN3*,*SLC7A1*,*CA2*,*CROT*
  GOTERM_MF_FAT   Cofactor binding                                                           15      1.22E‐04     ***XDH***,*TM7SF2*,*ALDH6A1*,*ECI2*,*KYNU*,*SORD*,*DUOX1*,***CBR3***,*ACADL*,*FMO5*,*SQLE*,***IDH1***,*HHIP*,*GAD1*,*GPT2*
  GOTERM_BP_FAT   Monocarboxylic acid metabolic process                                      22      1.29E‐04     *GGTA1P*,*PAM*,*ECI2*,*KYNU*,*SORD*,*CYP2J2*,*BCKDHB*,***PPARG***,*PDK4*,*CYP26A1*,*ACADL*,***CPT1A***,*ACSM3*,*PLA2G4A*,*ACSM1*,***IDH1***,*UGT8*,*SCD5*,*PCCA*,*DCXR*,*CROT*,*XYLB*
  GOTERM_BP_FAT   Organic acid metabolic process                                             30      1.40E‐04     *PAM*,*KYNU*,*CYP2J2*,*SORD*,***PPARG***,*AGMAT*,*FOLR1*,***IDH1***,*UGT8*,*SCD5*,*GAD1*,*GPT2*,*GGTA1P*,*ECI2*,*ALDH6A1*,*PDK4*,*BCKDHB*,*HGD*,*CYP26A1*,*CYB5A*,*ACADL*,***CPT1A***,*ACSM3*,*ACSM1*,*PLA2G4A*,*QPRT*,*PCCA*,*DCXR*,*CROT*,*XYLB*
  GOTERM_BP_FAT   Nitrogen compound transport                                                26      1.66E‐04     *CALHM1*,*SLC38A4*,*SLC15A2*,*OPRK1*,*TRH*,*SEC14L1*,*KCNS3*,*NOV*,*FOLR1*,***OXCT1***,*TAP2*,*SYBU*,*CHRNA6*,*SLC43A1*,*ABCA12*,*TRPM4*,*ISL1*,*GAL*,*PCLO*,***CPT1A***,*CHGA*,*SLC7A1*,*SYTL4*,*ACE2*,*GNAS*,*CA2*
  GOTERM_BP_FAT   Monocarboxylic acid catabolic process                                      9       1.86E‐04     *ECI2*,*SORD*,*CYP26A1*,*ACADL*,*PCCA*,*CROT*,***CPT1A***,*DCXR*,*XYLB*
  GOTERM_BP_FAT   Tissue morphogenesis                                                       23      2.03E‐04     *FRAS1*,*COBL*,*NF2*,*TNC*,*PML*,*NTN4*,*SIX3*,*FZD5*,*ISL1*,*MAGED1*,*ACTG2*,*EYA1*,*EPHA7*,*KRAS*,*PKP2*,*FOLR1*,*WNK4*,*TSC2*,*TFAP2A*,*NFATC4*,*CA2*,*HHIP*,*PRKACB*
  GOTERM_BP_FAT   Regulation of secretion                                                    25      2.20E‐04     *PAM*,*OPRK1*,*PML*,*POSTN*,*TLR6*,*TRH*,*KCNS3*,*NOV*,*CASP5*,*WNK4*,***OXCT1***,*SYBU*,*CHRNA6*,*MAP2K6*,*TRPM4*,*GAL*,*ISL1*,*NLRP2*,*PCLO*,***CPT1A***,*CHGA*,*STXBP6*,*SYTL4*,*GNAS*,*CPB2*
  GOTERM_BP_FAT   Epithelium development                                                     32      3.93E‐04     *FRAS1*,***XDH***,*COBL*,*TNC*,***PPARG***,*PML*,*CERS3*,*MAGED1*,*KRAS*,*MCOLN3*,*FOLR1*,*WNK4*,*UPK1B*,*NFATC4*,*HHIP*,*PRKACB*,*ABCA12*,*SMAD9*,*NF2*,*NTN4*,*SIX3*,*FZD5*,*GAL*,***CPT1A***,*EYA1*,*EPHA7*,*CLIC5*,*TSC2*,*TFAP2A*,*GNAS*,*CA2*,*LRP4*
  GOTERM_BP_FAT   Odontogenesis                                                              9       4.17E‐04     *ASPN*,*PAM*,*NF2*,*SLC24A4*,*TNC*,*COL1A2*,*TFAP2A*,*CA2*,*LRP4*
  GOTERM_BP_FAT   Regulation of secretion by cell                                            23      4.36E‐04     *TRPM4*,*PAM*,*OPRK1*,*PML*,*POSTN*,*TRH*,*TLR6*,*ISL1*,*GAL*,*PCLO*,*NLRP2*,***CPT1A***,*KCNS3*,*CASP5*,*NOV*,*CHGA*,*STXBP6*,***OXCT1***,*SYBU*,*SYTL4*,*GNAS*,*CHRNA6*,*CPB2*
  GOTERM_MF_FAT   Coenzyme binding                                                           11      8.04E‐04     *TM7SF2*,***XDH***,*ECI2*,*FMO5*,*ALDH6A1*,*SORD*,*SQLE*,*DUOX1*,***IDH1***,***CBR3***,*ACADL*
  GOTERM_BP_FAT   Chemical homeostasis                                                       31      8.72E‐04     *STEAP4*,*SLC39A14*,*ATP1B1*,***PPARG***,*PML*,*CKB*,*PDE6A*,*SLC24A4*,*ANK3*,*TAP2*,***OXCT1***,*WNK4*,*SLC39A8*,*PRKACB*,*ABCA12*,*TRPM4*,*HERPUD1*,*PDK4*,*TRIM24*,*GJB6*,*ACADL*,*ABCG1*,*ACSM3*,*SLC26A3*,*ACSM1*,*PLA2G4A*,*ATP6V0E2*,*PKP2*,*GNAS*,*CA2*,*CPB2*
  GOTERM_BP_FAT   Response to endogenous stimulus                                            42      8.80E‐04     *ASPN*,*PAM*,*KYNU*,*SORD*,*OPRK1*,*TNC*,***PPARG***,*DUOX1*,*PML*,*POSTN*,*GNG11*,*TRH*,*GREM2*,*PEA15*,*KRAS*,*FOLR1*,*GSN*,***OXCT1***,***IDH1***,*CHRNA6*,*PRKACB*,*RAMP2*,*SMAD9*,*STMN2*,*PDK4*,*TRIM24*,*GAL*,*ISL1*,*ABCG1*,*GJB2*,*SLC26A3*,*PLA2G4A*,*ATP6V0E2*,***HMGCS2***,*TSC2*,*COL1A2*,*GNAS*,*CA2*,*BMPR1B*,*HDAC9*,*CROT*,*LRP4*
  GOTERM_CC_FAT   Lamellipodium                                                              11      8.99E‐04     *ACTG2*,*SLC39A14*,*NF2*,*SORBS2*,*GSN*,*PLEKHH2*,*STMN2*,*NEDD9*,*IQGAP2*,*ITSN1*,*CTNNA2*
  GOTERM_BP_FAT   Secretion by cell                                                          29      .001130969   *PAM*,*NAAA*,*OPRK1*,*PML*,*POSTN*,*TLR6*,*TRH*,*KCNS3*,*CASP5*,*NOV*,***OXCT1***,*SYN2*,*SYBU*,*CREB3L1*,*CHRNA6*,*GAD1*,*ABCA12*,*TRPM4*,*ACTN1*,*ISL1*,*GAL*,*PCLO*,*NLRP2*,***CPT1A***,*CHGA*,*STXBP6*,*SYTL4*,*GNAS*,*CPB2*
  GOTERM_BP_FAT   Organ morphogenesis                                                        29      .001210502   *FRAS1*,*ASPN*,*PAM*,*TNC*,*PML*,*MAGED1*,*ACTG2*,*KRAS*,*SLC24A4*,*FOLR1*,*WNK4*,*HHIP*,*NF2*,*SIX3*,*NTN4*,*GJB6*,*FZD5*,*ISL1*,*CTNNA2*,*EYA1*,*PKP2*,*CLIC5*,*COL1A2*,*TFAP2A*,*GNAS*,*CA2*,*BMPR1B*,*CPB2*,*LRP4*
  GOTERM_BP_FAT   Regulation of biomineral tissue development                                7       .001363066   *ASPN*,*TRPM4*,*PLA2G4A*,*TFAP2A*,*BMPR1B*,*TMEM119*,*ANKH*
  GOTERM_BP_FAT   Regulation of protein secretion                                            16      .001462035   *TRPM4*,*PAM*,*PML*,*POSTN*,*TLR6*,*ISL1*,*TRH*,*NLRP2*,***CPT1A***,*KCNS3*,*NOV*,*CASP5*,***OXCT1***,*SYBU*,*SYTL4*,*GNAS*
  GOTERM_CC_FAT   Proteinaceous extracellular matrix                                         16      .001470486   *FRAS1*,*ASPN*,*HAPLN1*,*TNC*,*OLFML2B*,*NTN4*,*POSTN*,*COL5A3*,*NOV*,*OGN*,*BGN*,*ADAMTS8*,*KAZALD1*,*CCBE1*,*COL1A2*,*TFPI2*
  GOTERM_BP_FAT   Nervous system development                                                 52      .00156293    *ATL1*,***PPARG***,*POSTN*,*CKB*,*CASP5*,*CCDC141*,*OGN*,*PRMT1*,*MCOLN3*,*ANK3*,*GSN*,*PRKACB*,*HHIP*,*CDK5RAP2*,*PLCB1*,*ATOH7*,*TNIK*,*STMN2*,*SIX3*,*COL25A1*,*GAL*,*PCLO*,*CTNNA2*,*EYA1*,*CLIC5*,*TFAP2A*,*PAM*,*COBL*,*FRYL*,*TNC*,*KRAS*,*FOLR1*,***OXCT**1*,*NFATC4*,*NDRG2*,*UGT8*,*DCLK1*,*HAPLN1*,*SMAD9*,*NF2*,*NTN4*,*FZD5*,*ISL1*,*EPHA7*,***HMGCS2***,*TSC2*,*MAP2*,*MPPED2*,*HDAC9*,*BMPR1B*,*PHF8*,*LRP4*
  GOTERM_BP_FAT   Inorganic ion transmembrane transport                                      23      .001683334   *CALHM1*,*C15ORF48*,*TRPM4*,*SLC39A14*,*ATP1B1*,*TRPM6*,*OPRK1*,*CYB5A*,*GAL*,*ANKH*,*KCNIP4*,*KCNS3*, *SLC26A3*,*ATP6V0E2*,*ADAMTS8*,*SLC24A4*,*MCOLN3*,*ANK3*,*CLIC5*,*KCNN3*,*TTYH2*,*SLC39A8*,*ANO10*
  GOTERM_BP_FAT   Peptide hormone secretion                                                  12      .001842318   *KCNS3*,*TRPM4*,*NOV*,***OXCT1***,*SYBU*,*SYTL4*,*GNAS*,*ISL1*,*TRH*,*GAL*,*PCLO*,***CPT1A***
  GOTERM_BP_FAT   Regulation of insulin secretion                                            10      .001898558   *KCNS3*,*TRPM4*,*NOV*,***OXCT1***,*SYBU*,*SYTL4*,*GNAS*,*ISL1*,*TRH*,***CPT1A***
  GOTERM_BP_FAT   Regulation of peptide transport                                            11      .002159806   *KCNS3*,*TRPM4*,*NOV*,***OXCT1***,*SYBU*,*SYTL4*,*GNAS*,*CA2*,*ISL1*,*TRH*,***CPT1A***
  GOTERM_BP_FAT   Xylulose 5‐phosphate metabolic process                                     3       .002231113   *SORD*,*DCXR*,*XYLB*
  GOTERM_BP_FAT   Glucuronate catabolic process to xylulose 5‐phosphate                      3       .002231113   *SORD*,*DCXR*,*XYLB*
  GOTERM_BP_FAT   Xylulose 5‐phosphate biosynthetic process                                  3       .002231113   *SORD*,*DCXR*,*XYLB*
  GOTERM_BP_FAT   Glucuronate catabolic process                                              3       .002231113   *SORD*,*DCXR*,*XYLB*
  GOTERM_BP_FAT   Cation transport                                                           28      .002320182   *CALHM1*,*C15ORF48*,*SLC38A4*,*SLC39A14*,*STEAP4*,*ATP1B1*,*MFSD3*,*SLC15A2*,*OPRK1*,*PML*,*SEC14L1*, *KCNIP4*,*KCNS3*,*MCOLN3*,*SLC24A4*,*ANK3*, *WNK4*,*SLC39A8*,*CHRNA6*,*ANO10*,*TRPM4*, *RAMP2*,*TRPM6*,*CYB5A*,*GAL*,*ATP6V0E2*,*PKP2*,*KCNN3*
  GOTERM_BP_FAT   Peptide secretion                                                          12      .002431887   *KCNS3*,*TRPM4*,*NOV*,***OXCT1***,*SYBU*,*SYTL4*,*GNAS*,*ISL1*,*TRH*,*GAL*,*PCLO*,***CPT1A***
  GOTERM_BP_FAT   Morphogenesis of an epithelium                                             18      .002441073   *FRAS1*,*COBL*,*TNC*,*PML*,*NTN4*,*FZD5*,*MAGED1*,*EPHA7*,*EYA1*,*KRAS*,*FOLR1*,*WNK4*,*TSC2*,*TFAP2A*,*NFATC4*,*CA2*,*PRKACB*,*HHIP*
  GOTERM_BP_FAT   Anion transport                                                            17      .002448168   *SLC38A4*,***PPARG***,*TRH*,*ANKH*,***CPT1A***,*SLC26A3*,*PLA2G4A*,*ADAMTS8*,*CLIC5*,*TTYH2*,*SLC7A1*,*WNK4*,*CA2*,*SLC43A1*,*MAP2K6*,*CROT*,*ANO10*
  GOTERM_BP_FAT   Epithelial tube morphogenesis                                              13      .002731156   *COBL*,*TNC*,*PML*,*MAGED1*,*EYA1*,*EPHA7*,*KRAS*,*FOLR1*,*WNK4*,*TSC2*,*NFATC4*,*PRKACB*,*HHIP*
  GOTERM_BP_FAT   Signal release                                                             16      .002766541   *TRPM4*,*NAAA*,*OPRK1*,*ISL1*,*GAL*,*TRH*,*PCLO*,***CPT1A***, *KCNS3*,*NOV*,***OXCT1***,*SYN2*,*SYBU*,*SYTL4*,*GNAS*,*GAD1*
  GOTERM_BP_FAT   Regulation of hormone secretion                                            12      .002882484   *KCNS3*,*TRPM4*,*NOV*,*OPRK1*,***OXCT1***,*SYBU*,*SYTL4*,*GNAS*,*ISL1*,*TRH*,*GAL*,***CPT1A***
  GOTERM_BP_FAT   Protein localization                                                       55      .002908085   *COPA*,*ATP1B1*,*SLC15A2*,***PPARG***,*VPS37B*,*POSTN*,*SELENBP1*,*TLR6*,*KCNIP4*,*AP1S3*,*NOV*,*CASP5*,*ANK3*,*GSN*,*WNK4*,*TTC21A*,*TRPM4*,*RAMP2*,*TNIK*,*SIX3*,*GAL*,*NLRP2*,*PCLO*,*EYA1*,*HEPACAM*,*STXBP6*,*CLIC5*,*GNAS*,*FRAS1*,*PAM*,*PML*,*RABGAP1L*,*TRH*,*KCNS3*,*TMED3*,***OXCT1***,*TAP2*,*SYBU*,*UGT8*,*DCLK1*,*ABCA12*,*HERPUD1*,*NF2*,*ITGA4*,*FZD5*,*ISL1*,***CPT1A***,*ABCG1*,*ATP6V0E2*,*PKP2*,*KCNN3*,*TSC2*,*SYTL4*,*SNX30*,*LRP4*
  GOTERM_BP_FAT   Regulation of transport                                                    44      .002936176   *CALHM1*,*PAM*,*ATP1B1*,*OLFM4*,*OPRK1*,***PPARG***,*PML*,*VPS37B*,*RABGAP1L*,*POSTN*,*TLR6*,*TRH*,*KCNIP4*,*KCNS3*,*CASP5*,*NOV*,*PEA15*,*ANK3*,*WNK4*,***OXCT1***,*SYBU*,*CHRNA6*,*MAP2K6*,*SGIP1*,*ABCA12*,*TRPM4*,*FZD5*,*GAL*,*ISL1*,*NLRP2*,*PCLO*,*ABCG1*,***CPT1A***,*PLA2G4A*,*CHGA*,*STXBP6*,*PKP2*,*CLIC5*,*KCNN3*,*TSC2*,*SYTL4*,*GNAS*,*CA2*,*CPB2*
  GOTERM_BP_FAT   Hormone secretion                                                          13      .003111804   *TRPM4*,*OPRK1*,*GAL*,*TRH*,*ISL1*,*PCLO*,***CPT1A***,*KCNS3*,*NOV*,***OXCT1***,*SYTL4*,*SYBU*,*GNAS*
  GOTERM_BP_FAT   Protein secretion                                                          17      .003213878   *TRPM4*,*PML*,*POSTN*,*TRH*,*TLR6*,*ISL1*,*GAL*,*NLRP2*,*PCLO*,***CPT1A***,*KCNS3*,*NOV*,*CASP5*,***OXCT1***,*SYBU*,*SYTL4*,*GNAS*
  GOTERM_BP_FAT   Morphogenesis of a branching structure                                     10      .003228966   *MAGED1*,*EYA1*,*EPHA7*,*KRAS*,*TNC*,*PML*,*NTN4*,*NFATC4*,*HHIP*,*FZD5*
  GOTERM_BP_FAT   Insulin secretion                                                          9       .003253189   *TRPM4*,*NOV*,***OXCT1***,*SYBU*,*SYTL4*,*ISL1*,*TRH*,*GAL*,*PCLO*
  GOTERM_BP_FAT   Monovalent inorganic cation transport                                      17      .003456998   *C15ORF48*,*TRPM4*,*SLC38A4*,*ATP1B1*,*MFSD3*, *SLC15A2*,*OPRK1*,*CYB5A*,*GAL*,*KCNIP4*,*KCNS3*,*ATP6V0E2*,*SLC24A4*,*PKP2*,*ANK3*,*KCNN3*, *WNK4*
  GOTERM_BP_FAT   Regulation of hormone levels                                               17      .003534129   *TRPM4*,*OPRK1*,*DUOX1*,*CYP26A1*,*TRH*,*ISL1*,*GAL*,*PCLO*,***CPT1A***,*IYD*,*KCNS3*,*NOV*,***OXCT1***,*SYBU*,*SYTL4*,*ACE2*,*GNAS*
  GOTERM_CC_FAT   Golgi apparatus                                                            40      .003725799   *COPA*,*PAM*,*STEAP4*,*SLC39A14*,*ATL1*,***PPARG***,*NEDD9*,*RABGAP1L*,*POSTN*,*ST8SIA3*,*TLR6*,*SEC14L1*,*KCNS3*,*AP1S3*,*RNF125*,*OGN*,*GALNT10*,*TMED3*,*ANK3*,*FOLR1*,*SYBU*,*FUT3*,*CALN1*,*NDRG2*,*CDK5RAP2*,*MUC15*,*TRPM4*,*GGTA1P*,*STMN2*,*MUC7*,*FZD5*,*GAL*,*NLRP2*,*ABCG1*,*PLA2G4A*,*BGN*,*CLIC5*,*TSC2*,*TFAP2A*,*GNAS*
  GOTERM_MF_FAT   Sulfur compound binding                                                    11      .003932387   *NOV*,*ECI2*,*OGN*,*ALDH6A1*,*ADAMTS8*,*SERPINA5*,*COL25A1*,*POSTN*,*COL5A3*,*ACADL*,*GREM2*
  GOTERM_BP_FAT   Hormone transport                                                          13      .004094245   *TRPM4*,*OPRK1*,*GAL*,*TRH*,*ISL1*,*PCLO*,***CPT1A***,*KCNS3*,*NOV*,***OXCT1***,*SYTL4*,*SYBU*,*GNAS*
  GOTERM_BP_FAT   Dorsal/ventral pattern formation                                           7       .00420815    *SIX3*,*HHIP*,*PRKACB*,*BMPR1B*,*FZD5*,*GREM2*,*LRP4*
  GOTERM_CC_FAT   Perinuclear region of cytoplasm                                            22      .004356611   *DYNC1I1*,*CAPN6*,*COBL*,*PAM*,*OLFM4*,*TNIK*,*NF2*,*STMN2*,***PPARG***,*TPD52L1*,*FZD5*,*TPD52*,*CHGA*,*PLA2G4A*,*GSN*,*SORBS2*,*TSC2*,*GNAS*,*CALN1*,*NDRG2*,*CDK5RAP2*,*PRKACB*
  GOTERM_BP_FAT   Fatty acid metabolic process                                               14      .0044624     *GGTA1P*,*ECI2*,*PAM*,*CYP2J2*,***PPARG***,*PDK4*,*ACADL*, ***CPT1A***,*ACSM3*,*PLA2G4A*,*ACSM1*,*SCD5*,*PCCA*,*CROT*
  GOTERM_MF_FAT   Active transmembrane transporter activity                                  14      .004482151   *SLC26A3*,*SLC38A4*,*ATP1B1*,*ATP6V0E2*,*SLC24A4*,*MFSD3*,*SLC15A2*,*TAP2*,*SLC7A1*,*ABCC13*,*ANKH*,*ABCG1*,*ABCA12*,*SLC46A2*
  GOTERM_MF_FAT   Ion binding                                                                88      .004564204   *ASPN*,*STEAP4*,*ATP1B1*,*KYNU*,*CYP2J2*,*ATL1*,*ZFP42*,*ZNF530*,***PPARG***,*DUOX1*,*POSTN*,*TPD52*,*ITSN1*,*KCNIP4*,*SLC24A4*,*GSN*,*SERPINA5*,*CCBE1*,*CALN1*,*CHRNA6*,*HHIP*,*PRKACB*,*SCD5*,*PLCB1*,*GPT2*,*NUDT16*,*TRPM6*,*PLD6*,*CYP26A1*,*ACTN1*,*CYB5A*,*PCLO*,*NME7*,*NEBL*,*ZNF233*,*EYA1*,*ADAMTS8*,*CA8*,*CAPN12*,*COL1A2*,*GNAS*,*ADAM18*,*CA2*,*ADAM12*,*PCCA*,*ZNF436*,*FRAS1*,*CAPS*,***XDH***,*PAM*,*SORD*,*YPEL4*,*PML*,*ST8SIA3*,*AGMAT*,*PDE6A*,*RNF125*,*KRAS*,*GALNT10*,*TCEA3*,*FOLR1*,*SORBS2*,*PDE1A*,***IDH1***,*GAD1*,*SMAD9*,*IKZF2*,*PDZRN4*,*VWCE*,*HGD*,*TRIM24*,*ITGA4*,*CSRP2*,*ISL1*,*XPNPEP2*,*ACSM3*,*PAPOLA*,*ACSM1*,*PLA2G4A*,*ZIC4*,*SYTL4*,*ACE2*,*MPPED2*,*HDAC9*,*BMPR1B*,*PHF8*,*CPB2*,*LRP4*
  GOTERM_BP_FAT   Regulation of bone mineralization                                          6       .004761268   *TRPM4*,*PLA2G4A*,*TFAP2A*,*BMPR1B*,*TMEM119*,*ANKH*
  GOTERM_BP_FAT   Extracellular matrix organization                                          13      .005198597   *RAMP2*,*HAPLN1*,*BGN*,*GSN*,*KAZALD1*,*TNC*,*OLFML2B*,*COL1A2*,*CREB3L1*,*POSTN*,*ITGA4*,*COL5A3*,*CPB2*
  GOTERM_BP_FAT   Cellular response to chemical stimulus                                     58      .00526536    *ASPN*,*CYP2J2*,***PPARG***,*DUOX1*,*POSTN*,*NOV*,*ANK3*,*GSN*,*CCBE1*,*CREB3L1*,*PRKACB*,*HHIP*,*PLCB1*,*MAP2K6*,*IFNGR1*,*TRPM4*,*RAMP2*,*STMN2*,*CYP26A1*,*SERPINB9*,*SLC26A3*,*CHGA*,*BGN*,*COL1A2*,*TFAP2A*,*GNAS*,*CA2*,***XDH***,*OPRK1*,*TNC*,*PML*,*GNG11*,*TRH*,*GREM2*,*KRAS*,*FOLR1*,***OXCT**1*,*NFATC4*,*THPO*,*HERPUD1*,*SMAD9*,*PDK4*,*ITGA4*,*TRIM24*,*GJB6*,*ISL1*,***CPT1A***,*GJB2*,*PLA2G4A*,*ACSM1*,*ATP6V0E2*,*GPR37*,***HMGCS2***,*TSC2*,*HDAC9*,*BMPR1B*,*CPB2*,*LRP4*
  GOTERM_BP_FAT   Extracellular structure organization                                       13      .00532233    *RAMP2*,*HAPLN1*,*BGN*,*GSN*,*KAZALD1*,*TNC*,*OLFML2B*,*COL1A2*,*CREB3L1*,*POSTN*,*ITGA4*,*COL5A3*,*CPB2*
  GOTERM_MF_FAT   Glycosaminoglycan binding                                                  10      .005386366   *NOV*,*OGN*,*HAPLN1*,*BGN*,*ADAMTS8*,*SERPINA5*,*COL25A1*,*POSTN*,*COL5A3*,*GREM2*
  GOTERM_BP_FAT   Positive regulation of stress‐activated MAPK cascade                       8       .005588879   ***XDH***,*PRMT1*,*TNIK*,*OPRK1*,*TPD52L1*,*TLR6*,*FZD5*,*PLCB1*
  GOTERM_BP_FAT   Regulation of peptide hormone secretion                                    10      .005698819   *KCNS3*,*TRPM4*,*NOV*,***OXCT1***,*SYBU*,*SYTL4*,*GNAS*,*ISL1*,*TRH*,***CPT1A***
  GOTERM_BP_FAT   Morphogenesis of a branching epithelium                                    9       .005744299   *MAGED1*,*EYA1*,*KRAS*,*TNC*,*PML*,*NTN4*,*NFATC4*,*HHIP*,*FZD5*
  GOTERM_BP_FAT   Positive regulation of stress‐activated protein kinase signaling cascade   8       .005806735   ***XDH***,*PRMT1*,*TNIK*,*OPRK1*,*TPD52L1*,*TLR6*,*FZD5*,*PLCB1*
  GOTERM_MF_FAT   NADP binding                                                               5       .006314099   *TM7SF2*,*FMO5*,*DUOX1*,***IDH1***,***CBR3***
  GOTERM_BP_FAT   Ion transmembrane transport                                                26      .006573948   *CALHM1*,*C15ORF48*,*SLC39A14*,*ATP1B1*,*OPRK1*,*KCNIP4*,*KCNS3*,*MCOLN3*,*SLC24A4*,*ANK3*,*TTYH2*,*WNK4*,*SLC39A8*,*CHRNA6*,*ANO10*,*TRPM4*,*TRPM6*,*CYB5A*,*GAL*,*ANKH*,***CPT1A***,*SLC26A3*,*ATP6V0E2*,*ADAMTS8*,*KCNN3*,*CLIC5*
  GOTERM_BP_FAT   Regulation of peptide secretion                                            10      .006609351   *KCNS3*,*TRPM4*,*NOV*,***OXCT1***,*SYBU*,*SYTL4*,*GNAS*,*ISL1*,*TRH*,***CPT1A***
  GOTERM_BP_FAT   Response to hormone                                                        25      .00677892    *PAM*,*SORD*,*TNC*,*OPRK1*,***PPARG***,*GNG11*,*TRH*,*KRAS*,***OXCT1***,***IDH1***,*PRKACB*,*RAMP2*,*PDK4*,*TRIM24*,*ISL1*,*GAL*,*ABCG1*,*GJB2*,*PLA2G4A*,*ATP6V0E2*,***HMGCS2***,*TSC2*,*GNAS*,*CA2*,*HDAC9*
  GOTERM_BP_FAT   Response to vitamin                                                        7       .006968045   *PLA2G4A*,*KYNU*,*FOLR1*,*GSN*,*TNC*,***PPARG***,*POSTN*
  GOTERM_BP_FAT   Homeostatic process                                                        39      .006995908   *STEAP4*,*SLC39A14*,*ATP1B1*,*OPRK1*,***PPARG***,*PML*,*CKB*,*NOV*,*PDE6A*,*PRMT1*,*KRAS*,*SLC24A4*,*ANK3*,*TAP2*,*WNK4*,***OXCT1***,*SYBU*,*SLC39A8*,*PRKACB*,*SGIP1*,*ABCA12*,*TRPM4*,*HERPUD1*,*HMBOX1*,*PDK4*,*TRIM24*,*GJB6*,*ACADL*,*ABCG1*,*ACSM3*,*SLC26A3*,*PLA2G4A*,*ACSM1*,*ATP6V0E2*,*PKP2*,*GNAS*,*CA2*,*CPB2*,*SLC46A2*
  GOTERM_BP_FAT   Tube morphogenesis                                                         13      .00712882    *COBL*,*TNC*,*PML*,*MAGED1*,*EYA1*,*EPHA7*,*KRAS*,*FOLR1*,*WNK4*,*TSC2*,*NFATC4*,*PRKACB*,*HHIP*
  GOTERM_BP_FAT   Response to organic substance                                              61      .007992486   *ASPN*,*KYNU*,***PPARG***,*DUOX1*,*POSTN*,*TLR6*,*GSN*,*CCBE1*,*CREB3L1*,*CHRNA6*,*PRKACB*,*HHIP*,*PLCB1*,*MAP2K6*,*IFNGR1*,*TRPM4*,*RAMP2*,*STMN2*,*GAL*,*SLC26A3*,*BGN*,*SQLE*,*COL1A2*,*TFAP2A*,*GNAS*,*CA2*,*CROT*,***XDH***,*PAM*,*SORD*,*OPRK1*,*TNC*,*PML*,*GNG11*,*TRH*,*GREM2*,*PEA15*,*KRAS*,*FOLR1*,***OXCT1***,***IDH1***,*THPO*,*HERPUD1*,*SMAD9*,*PDK4*,*ITGA4*,*TRIM24*,*GJB6*,*FZD5*,*ISL1*,***CPT1A***,*ABCG1*,*GJB2*,*PLA2G4A*,*ATP6V0E2*,***HMGCS2***,*TSC2*,*HDAC9*,*BMPR1B*,*CPB2*,*LRP4*
  GOTERM_CC_FAT   Cell leading edge                                                          14      .008364418   *COBL*,*SLC39A14*,*NF2*,*STMN2*,*NEDD9*,*IQGAP2*,*ACTN1*,*ITSN1*,*CTNNA2*,*ACTG2*,*GSN*,*SORBS2*,*PLEKHH2*,*GNAS*
  GOTERM_BP_FAT   Regulation of peptidase activity                                           14      .008369752   ***XDH***,*SERPINB9*,*HERPUD1*,*EPHA7*,*CARD16*,*GSN*,*SERPINA5*,***PPARG***,*PML*,*CST1*,*NLRP2*,*TFPI2*,*WFDC2*,*PI15*
  GOTERM_BP_FAT   Macromolecule localization                                                 59      .009247219   *COPA*,*ATP1B1*,*SLC15A2*,***PPARG***,*VPS37B*,*POSTN*,*SELENBP1*,*TLR6*,*KCNIP4*,*CASP5*,*NOV*,*AP1S3*,*ANK3*,*GSN*,*SERPINA5*,*WNK4*,*TTC21A*,*MAP2K6*,*TRPM4*,*RAMP2*,*TNIK*,*SIX3*,*GAL*,*NLRP2*,*PCLO*,*EYA1*,*HEPACAM*,*STXBP6*,*CLIC5*,*GNAS*,*CROT*,*FRAS1*,*PAM*,*PML*,*RABGAP1L*,*TRH*,*KCNS3*,*TMED3*,*TAP2*,***OXCT1***,*SYBU*,*UGT8*,*DCLK1*,*ABCA12*,*HERPUD1*,*NF2*,*ITGA4*,*FZD5*,*ISL1*,***CPT1A***,*ABCG1*,*PLA2G4A*,*ATP6V0E2*,*PKP2*,*KCNN3*,*TSC2*,*SYTL4*,*SNX30*,*LRP4*
  GOTERM_BP_FAT   Glucuronate metabolic process                                              4       .009462291   *SORD*,*UGT8*,*DCXR*,*XYLB*
  GOTERM_BP_FAT   Regulation of fatty acid oxidation                                         4       .009462291   *PDK4*,***PPARG***,*ACADL*,***CPT1A***
  GOTERM_BP_FAT   Uronic acid metabolic process                                              4       .009462291   *SORD*,*UGT8*,*DCXR*,*XYLB*
  GOTERM_BP_FAT   Response to estrogen                                                       6       .009528125   *SERPINB9*,*OPRK1*,***PPARG***,*TRIM24*,*CA2*,*GAL*
  GOTERM_BP_FAT   Axon development                                                           15      .009632965   *COBL*,*ATL1*,*TNC*,*NTN4*,*COL25A1*,*ISL1*,*CTNNA2*,*OGN*,*EPHA7*,*KRAS*,*FOLR1*,*ANK3*,*BMPR1B*,*LRP4*,*DCLK1*
  GOTERM_BP_FAT   Organonitrogen compound catabolic process                                  13      .009943818   ***XDH***,*NUDT16*,*ALDH6A1*,*KYNU*,*BCKDHB*,*HGD*,*ACADL*,*OGN*,*BGN*,*PDE1A*,*ACE2*,*GAD1*,*GPT2*

MAPK, mitogen‐activated protein kinase; NADP, nicotinamide adenine dinucleotide phosphate. Bold denotes gene names which are picked up in the results and discussion.
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In addition, several of the down‐regulated genes (peroxisome proliferator‐activated receptor γ \[*PPAR‐*γ\], xanthine dehydrogenase \[*XDH*\], carbonyl reductase 3 \[*CBR3*\], isocitrate dehydrogenase 1 \[*IDH1*\], and *CPT1*) fell under the GO term "oxidation‐reduction process" (Tables [4](#rmb212030-tbl-0004){ref-type="table-wrap"} and [S1](#rmb212030-sup-0001){ref-type="supplementary-material"}). These genes have essential roles in the response to oxidative stress.[15](#rmb212030-bib-0015){ref-type="ref"}, [16](#rmb212030-bib-0016){ref-type="ref"}, [17](#rmb212030-bib-0017){ref-type="ref"}, [18](#rmb212030-bib-0018){ref-type="ref"}, [19](#rmb212030-bib-0019){ref-type="ref"}, [20](#rmb212030-bib-0020){ref-type="ref"}, [21](#rmb212030-bib-0021){ref-type="ref"}, [22](#rmb212030-bib-0022){ref-type="ref"}, [23](#rmb212030-bib-0023){ref-type="ref"}, [24](#rmb212030-bib-0024){ref-type="ref"}, [25](#rmb212030-bib-0025){ref-type="ref"}

Two KEGG pathways that have a strong association with the down‐regulated genes are "butanoate metabolism" and "metabolic pathways" (Tables [5](#rmb212030-tbl-0005){ref-type="table-wrap"} and [S2](#rmb212030-sup-0002){ref-type="supplementary-material"}). These pathways include *HMGCS2, OXCT1*,*XDH*,*IDH1*, and *CBR3*.

###### 

Kyoto Encyclopedia of Genes and Genomes pathway analysis for the genes that were down‐regulated in the thin endometrium

  Term                                                        Count   *P* value    Gene
  ----------------------------------------------------------- ------- ------------ ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Butanoate metabolism                                        5       .001114534   *ACSM3*,*ACSM1*,***HMGCS2***,***OXCT1***,*GAD1*
  Metabolic pathways                                          34      .005119787   *TM7SF2*,***XDH***,*KYNU*,*SORD*,*CYP2J2*,*CERS4*,*CERS3*,*AGMAT*,*CKB*,*GALNT10*,*FUT3*,***IDH1***,*UGT8*,*PLCB1*,*GAD1*,*GPT2*,*ALDH6A1*,*BCKDHB*,*HGD*,*ALDH3B2*,*CYP26A1*,***CBR3***,*ACADL*,*NME7*,*ACSM3*,*PLA2G4A*,*ACSM1*,*ATP6V0E2*,***HMGCS2***,*SQLE*,*QPRT*,*PCCA*,*DCXR*,*XYLB*
  Thyroid hormone synthesis                                   6       .007157684   *ATP1B1*,*CREB3L1*,*GNAS*,*PRKACB*,*PLCB1*,*IYD*
  Valine, leucine, and isoleucine degradation                 5       .00867887    *ALDH6A1*,***HMGCS2***,***OXCT1***,*BCKDHB*,*PCCA*
  Amoebiasis                                                  7       .01007625    *SERPINB9*,*COL1A2*,*ACTN1*,*GNAS*,*PRKACB*,*COL5A3*,*PLCB1*
  Serotonergic synapse                                        7       .012474846   *PLA2G4A*,*CYP2J2*,*KRAS*,*GNG11*,*GNAS*,*PRKACB*,*PLCB1*
  Salivary secretion                                          6       .016558258   *ATP1B1*,*CST1*,*GNAS*,*MUC7*,*PRKACB*,*PLCB1*
  Protein digestion and absorption                            6       .018126807   *ATP1B1*,*COL1A2*,*ACE2*,*COL5A3*,*CPB2*,*XPNPEP2*
  GnRH signaling pathway                                      6       .020659132   *PLA2G4A*,*KRAS*,*GNAS*,*PRKACB*,*PLCB1*,*MAP2K6*
  Pancreatic secretion                                        6       .022469965   *SLC26A3*,*ATP1B1*,*GNAS*,*CA2*,*PLCB1*,*CPB2*
  Inflammatory mediator regulation of TRP channels            6       .027439494   *PLA2G4A*,*CYP2J2*,*GNAS*,*PRKACB*,*PLCB1*,*MAP2K6*
  Glucagon signaling pathway                                  6       .028510884   *PRMT1*,*CREB3L1*,*GNAS*,*PRKACB*,*PLCB1*,*CPT1A*
  Melanogenesis                                               6       .029608533   *KRAS*,*CREB3L1*,*GNAS*,*PRKACB*,*FZD5*,*PLCB1*
  Arrhythmogenic right ventricular cardiomyopathy             5       .034477703   *PKP2*,*SGCD*,*ACTN1*,*ITGA4*,*CTNNA2*
  Gastric acid secretion                                      5       .037626762   *ATP1B1*,*GNAS*,*PRKACB*,*CA2*,*PLCB1*
  Vasopressin‐regulated water reabsorption                    4       .040391867   *DYNC1I1*,*CREB3L1*,*GNAS*,*PRKACB*
  Endocrine and other factor‐regulated calcium reabsorption   4       .04274525    *ATP1B1*,*GNAS*,*PRKACB*,*PLCB1*
  Cholinergic synapse                                         6       .043457379   *KRAS*,*CREB3L1*,*GNG11*,*PRKACB*,*CHRNA6*,*PLCB1*

GnRH, gonadotropin‐releasing hormone; TRP, transient receptor potential. Bold denotes gene names which are picked up in the results and discussion.
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4. Discussion {#rmb212030-sec-0014}
=============

4.1. Up‐regulated genes in the thin endometrium {#rmb212030-sec-0015}
-----------------------------------------------

Although a thin endometrium is known to be involved in implantation failure, the mechanism has not been elucidated. The authors recently found that a high level of blood flow impedance of the uterine radial artery underlies a thin endometrium.[4](#rmb212030-bib-0004){ref-type="ref"} The present study investigated the cause of implantation failure in the thin endometrium by using genome‐wide mRNA expression analysis. Hierarchical clustering and a PCA demonstrated that the thin endometrium and the control endometrium clearly had different mRNA expression profiles, suggesting that aberrant gene expression is involved in implantation failure in a thin endometrium.

The GO analyses showed that the up‐regulated genes in the thin endometrium included a number of genes that are related to immunity. In fact, a KEGG pathway analysis indicated that a number of genes related to natural killer cell cytotoxicity are up‐regulated in thin endometria, suggesting the presence of a cytotoxic condition. Aberrant immunological factors play roles in recurrent miscarriage and implantation failure.[6](#rmb212030-bib-0006){ref-type="ref"}, [26](#rmb212030-bib-0026){ref-type="ref"}, [27](#rmb212030-bib-0027){ref-type="ref"} Interestingly, 56.6% of the patients who experienced embryo implantation failures showed local immune overactivation in the endometrium at the mid‐luteal phase.[6](#rmb212030-bib-0006){ref-type="ref"} An influx of immune cells and a switch of local immunity from the adaptive (Th1) type to the innate (Th2) type have been observed during the implantation window.[6](#rmb212030-bib-0006){ref-type="ref"}, [28](#rmb212030-bib-0028){ref-type="ref"} The Th2 cytokines allow the development of local mechanisms that promote immunotrophism and also down‐regulate the inflammation and cytotoxic pathways.[6](#rmb212030-bib-0006){ref-type="ref"}, [29](#rmb212030-bib-0029){ref-type="ref"} This immune switch, from a Th1 pro‐inflammatory environment to a Th2 anti‐inflammatory environment, is fundamental to the establishment of local maternal tolerance and is crucial for implantation. In this period, uterine natural killer (uNK) cells, together with macrophages and dendritic cells, increase in the endometrium and have a significant role in innate (Th2) immunity.[30](#rmb212030-bib-0030){ref-type="ref"} Unlike peripheral natural killer cells, the uNK cells are not cytotoxic and their main biological functions are to produce immunotrophic and angiogenic cytokines. The activation of adequate uNK cells is important for maternal tolerance during the implantation window.[31](#rmb212030-bib-0031){ref-type="ref"}, [32](#rmb212030-bib-0032){ref-type="ref"}, [33](#rmb212030-bib-0033){ref-type="ref"} However, once the uNK cells are highly activated, a Th1 pro‐inflammatory condition is induced, with the local production of *IFN‐*γ and *TNF‐*α.[34](#rmb212030-bib-0034){ref-type="ref"}, [35](#rmb212030-bib-0035){ref-type="ref"} The *IFN‐*γ and *TNF‐*α activate the uNK cells to become cytotoxic.[34](#rmb212030-bib-0034){ref-type="ref"}, [35](#rmb212030-bib-0035){ref-type="ref"} In fact, the present study showed that the *IFN‐*γ, *FASLG*,*GZMB*,*and TNF‐*α‐induced genes, such as *TNFAIP2* and *TNFAIP6*, were up‐regulated and that natural killer cell cytotoxicity was elevated in the thin endometrium. These results suggest that aberrant overactivation of the uNK cells and a cytotoxic/Th1 pro‐inflammatory environment are present in a thin endometrium, which is associated with implantation failure. However, it is still unknown how impaired blood flow is associated with the aberrant immunity.

4.2. Down‐regulated genes in the thin endometrium {#rmb212030-sec-0016}
-------------------------------------------------

The GO analyses indicated that the down‐regulated genes included a number of genes related to catabolic processes, which are essential in breaking down large molecules, such as polysaccharides, lipids, and proteins, into smaller units, such as monosaccharides, fatty acids, and amino acids. These small units are used to synthesize acetyl‐CoA, which is needed to produce adenosine 5′‐triphosphate in the citrate cycle. Acetyl‐CoA is also used for the synthesis of ketone bodies, which can be an energy source. The KEGG pathway analysis showed that the genes related to butanoate metabolism were down‐regulated in the thin endometrium. Genes, such as *CPT1*,*HMGCS2*, and *OXCT1*, are essential for generating acetyl‐CoA and ketone bodies in butanoate metabolism.[13](#rmb212030-bib-0013){ref-type="ref"}, [14](#rmb212030-bib-0014){ref-type="ref"}, [15](#rmb212030-bib-0015){ref-type="ref"} Butanoate is a substrate that is used to generate energy in both aerobic and anaerobic processes. The present findings suggest that energy synthesis in the cell is impaired in the thin endometrium. The deficiency of energy could be associated with cellular dysfunction in the endometrium, resulting in implantation failure.

The GO analyses also identified a number of genes related to oxidation‐reduction processes. These genes included *PPAR‐*γ, *XDH*,*CBR3*,*IDH1*, and *CPT1*, which have essential roles in the cellular responses to oxidative stress. The activation of *PPAR‐*γ is an important factor in the protection against oxidative stress in cells, such as vascular endothelial cells and cardiomyocytes.[16](#rmb212030-bib-0016){ref-type="ref"}, [17](#rmb212030-bib-0017){ref-type="ref"}, [20](#rmb212030-bib-0020){ref-type="ref"}, [21](#rmb212030-bib-0021){ref-type="ref"}, [24](#rmb212030-bib-0024){ref-type="ref"}, [25](#rmb212030-bib-0025){ref-type="ref"} Xanthine dehydrogenase reduces age‐related oxidative stress in tissues and immune cells.[23](#rmb212030-bib-0023){ref-type="ref"} Carbonyl reductase 3 is regulated via *NRF2*‐dependent signaling pathways and helps to alleviate oxidative stress.[18](#rmb212030-bib-0018){ref-type="ref"} Isocitrate dehydrogenase 1 acts as an antioxidant in melanocytes,[19](#rmb212030-bib-0019){ref-type="ref"} and when mutated, it sensitizes cells to oxidative stress.[36](#rmb212030-bib-0036){ref-type="ref"} Carnitine palmitoyltransferase I is involved in mitochondrial beta‐oxidation of long‐chain fatty acids.[15](#rmb212030-bib-0015){ref-type="ref"} The inhibition of *CPT1* leads to the generation of reactive oxygen species.[22](#rmb212030-bib-0022){ref-type="ref"} Oxidative stress in the endometrium has been associated with failures of embryo implantation and embryo development.[37](#rmb212030-bib-0037){ref-type="ref"} The fact that these anti‐oxidative stress genes were down‐regulated in the thin endometrium suggests that a decreased response to oxidative stress is associated with implantation failure.

In conclusion, the present study revealed that the thin endometrium possesses an aberrant Th1‐pro‐inflammatory/Th2‐anti‐inflammatory balance and increased cytotoxic condition and that a protective response to oxidative stress is impaired. These aberrant molecular mechanisms in the thin endometrium might be associated with implantation failure. These findings could lead to better treatments for patients with implantation failure as a result of a thin endometrium.
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